Belgian Cancer Registry

CANCER FACT SHEET 2024
TUMOUR OF THE CENTRAL NERVOUS SYSTEM
ICD-10 C70-C72, C75.1-C75.3, D42-D43, D44.3-D44.5, D32-D33, D35.2-D35.4

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

Throughout this cancer fact sheet, results are presented based on sex and age group of patients and behaviour of the tumour (benign, borderline and malignant). This ICD-O-3 behavioural classification may not completely reflect the classical clinical classification of CNS tumours which is based on WHO grade of CNS tumours (I-IV). Nevertheless, this fact sheet describes data based on the behaviour of tumours to keep consistency with international reports. Moreover, this WHO grade was not systematically recorded in the past and is not applicable to all CNS tumours (e.g. haematolymphoid tumours involving the CNS).

Sublocations of the tumours in central nervous system:

- **C70:** Meninges
- **C71:** Brain
- **C72:** Spinal cord and other parts of the central nervous system
- **C75.1:** Pituitary gland
- **C75.2:** Craniopharyngeal duct
- **C75.3:** Pineal gland

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Tumour of the central nervous system incidence: by tumour behaviour 5

1.1.1. Tumour of the central nervous system incidence by behaviour and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Tumour of the central nervous system incidence: by tumour behaviour and tumour location 6

1.2.1. Tumour of the central nervous system incidence by behaviour, location, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 6

2. CANCER INCIDENCE TRENDS 7

2.1. Tumour of the central nervous system incidence trends: by tumour behaviour 7

2.1.1. Tumour of the central nervous system incidence trends by behaviour in males: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 7

2.1.2. Tumour of the central nervous system incidence trends by behaviour in females: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 9

2.2. Tumour of the central nervous system incidence trends: by tumour location 10

2.2.1. Tumour of the central nervous system incidence trends by location in males: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 10

2.2.2. Tumour of the central nervous system incidence trends by location in females: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 12

2.3. Tumour of the central nervous system incidence trends: by tumour behaviour and age group 14

2.3.1. Tumour of the central nervous system incidence trends in males, by behaviour and age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 14

2.3.2. Tumour of the central nervous system incidence trends in females, by behaviour and age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 17

3. CANCER PREVALENCE 20

3.1. Tumour of the central nervous system prevalence: by tumour behaviour and region 20

3.1.1. Tumour of the central nervous system prevalence by behaviour, region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 20

4. CANCER SURVIVAL 23

4.1. Tumour of the central nervous system survival: by tumour behaviour 23

4.1.1. Tumour of the central nervous system survival by behaviour, age group and sex: number at risk and net survival probabilities, 2015-2024 23

4.2. Tumour of the central nervous system survival: by tumour behaviour and tumour location 25

4.2.1. Tumour of the central nervous system survival by behaviour, location, and sex: number at risk and net survival probabilities, 2015-2024 25

5. CANCER SURVIVAL TRENDS 28

5.1. Tumour of the central nervous system survival trends: by tumour behaviour 28

5.1.1. Tumour of the central nervous system survival trends by behaviour and sex: number at risk and net survival probabilities, 2004-2024 28
5.2. Tumour of the central nervous system survival trends: by tumour behaviour and tumour location 29
5.2.1. Tumour of the central nervous system survival trends by behaviour, location and sex: number at risk and net survival probabilities, 2004-2024 29
6. CANCER MORTALITY 33
6.1. Tumour of the central nervous system mortality: by tumour behaviour and region 33
6.1.1. Tumour of the central nervous system mortality* by behaviour, region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 33
7. CANCER MORTALITY TRENDS 36
7.1. Tumour of the central nervous system mortality trends: by tumour behaviour and region 36
7.1.1. Tumour of the central nervous system mortality* trends in males, by behaviour and region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 36
7.1.2. Tumour of the central nervous system mortality* trends in females, by behaviour and region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 39

1.1. Tumour of the central nervous system incidence: by tumour behaviour

1.1.1. Tumour of the central nervous system incidence by behaviour and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Behaviour	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Malignant	9	5	5	12	14	17	29	26	40	57	67	69	99	87	88	75	48	24	1	0	772	13.6
	[3.0]	[1.5]	[1.4]	[3.4]	[4.0]	[4.7]	[7.4]	[6.8]	[10.4]	[15.3]	[17.0]	[17.3]	[26.1]	[26.8]	[32.8]	[35.2]	[37.9]	[29.2]	[3.1]	[0.0]	[13.3]	(12.6; 14.6)
Borderline	9	7	7	4	5	4	6	7	5	4	10	7	11	8	13	7	5	2	0	0	121	2.1
	[3.0]	[2.1]	[2.0]	[1.1]	[1.4]	[1.1]	[1.5]	[1.8]	[1.3]	[1.1]	[2.5]	[1.8]	[2.9]	[2.5]	[4.8]	[3.3]	[4.0]	[2.4]	[0.0]	[0.0]	[2.1]	(1.7; 2.5)
Benign	2	3	0	3	2	6	10	15	15	22	26	34	42	43	34	37	19	15	6	2	336	6.0
	[0.7]	[0.9]	[0.0]	[0.9]	[0.6]	[1.6]	[2.6]	[3.9]	[3.9]	[5.9]	[6.6]	[8.5]	[11.1]	[13.2]	[12.7]	[17.4]	[15.0]	[18.3]	[18.4]	[31.4]	[5.8]	(5.3; 6.6)
Females																						
Malignant	4	10	6	10	16	29	35	32	37	39	29	49	54	55	58	46	36	14	3	0	562	9.3
	[1.4]	[3.2]	[1.8]	[3.0]	[4.8]	[8.0]	[8.9]	[8.3]	[9.6]	[10.5]	[7.5]	[12.5]	[14.0]	[15.9]	[19.4]	[18.0]	[20.7]	[10.3]	[4.2]	[0.0]	[9.4]	(8.5; 10.1)
Borderline	6	9	9	5	3	9	8	5	8	12	12	15	9	10	5	4	2	1	1	0	133	2.3
	[2.1]	[2.9]	[2.7]	[1.5]	[0.9]	[2.5]	[2.0]	[1.3]	[2.1]	[3.2]	[3.1]	[3.8]	[2.3]	[2.9]	[1.7]	[1.6]	[1.2]	[0.7]	[1.4]	[0.0]	[2.2]	(1.9; 2.6)
Benign	1	0	3	2	5	2	25	28	75	81	123	120	104	101	96	100	54	49	9	4	982	16.1
	[0.3]	[0.0]	[0.9]	[0.6]	[1.5]	[0.6]	[6.4]	[7.3]	[19.4]	[21.9]	[31.9]	[30.6]	[26.9]	[29.3]	[32.2]	[39.1]	[31.1]	[36.2]	[12.5]	[18.5]	[16.5]	(15.1; 17.1)

1.2. Tumour of the central nervous system incidence: by tumour behaviour and tumour location

1.2.1. Tumour of the central nervous system incidence by behaviour, location, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Behaviour	Location	Males						Females					
		N[CR]					ESR2013 (95%CI)	N[CR]					ESR2013 (95%CI)
		0-19	20-39	40-64	65+	All ages 0+		0-19	20-39	40-64	65+	All ages 0+	
Malignant	**C70**	0 [0.0]	0 [0.0]	2 [0.1]	3 [0.3]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	1 [0.1]	4 [0.2]	2 [0.2]	7 [0.1]	0.1 (0.0; 0.2)
	C71	27 [2.0]	54 [3.6]	227 [11.8]	246 [23.3]	554 [9.6]	9.7 (8.9; 10.6)	20 [1.6]	45 [3.1]	114 [5.9]	166 [12.7]	345 [5.8]	5.6 (5.0; 6.2)
	C72	1 [0.1]	3 [0.2]	9 [0.5]	2 [0.2]	15 [0.3]	0.3 (0.1; 0.4)	1 [0.1]	6 [0.4]	4 [0.2]	2 [0.2]	13 [0.2]	0.2 (0.1; 0.3)
	C75.1	2 [0.2]	29 [2.0]	94 [4.9]	72 [6.8]	197 [3.4]	3.5 (3.0; 4.0)	8 [0.6]	59 [4.0]	85 [4.4]	40 [3.1]	192 [3.2]	3.3 (2.8; 3.8)
	C75.2	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	C75.3	1 [0.1]	0 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)	1 [0.1]	1 [0.1]	1 [0.1]	2 [0.2]	5 [0.1]	0.1 (0.0; 0.2)
Borderline	**C70**	0 [0.0]	2 [0.1]	10 [0.5]	15 [1.4]	27 [0.5]	0.5 (0.3; 0.7)	1 [0.1]	3 [0.2]	23 [1.2]	11 [0.8]	38 [0.6]	0.6 (0.4; 0.8)
	C71	16 [1.2]	13 [0.9]	17 [0.9]	17 [1.6]	63 [1.1]	1.1 (0.8; 1.3)	18 [1.4]	15 [1.0]	19 [1.0]	7 [0.5]	59 [1.0]	1.0 (0.8; 1.3)
	C72	8 [0.6]	4 [0.3]	8 [0.4]	1 [0.1]	21 [0.4]	0.4 (0.2; 0.5)	9 [0.7]	5 [0.3]	5 [0.3]	1 [0.1]	20 [0.3]	0.3 (0.2; 0.5)
	C75.1	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	1 [0.1]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
	C75.2	3 [0.2]	3 [0.2]	1 [0.1]	2 [0.2]	9 [0.2]	0.2 (0.1; 0.3)	1 [0.1]	0 [0.0]	6 [0.3]	4 [0.3]	11 [0.2]	0.2 (0.1; 0.3)
	C75.3	0 [0.0]	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	1 [0.1]	3 [0.2]	0 [0.0]	4 [0.1]	0.1 (0.0; 0.1)
Benign	**C70**	2 [0.2]	14 [0.9]	96 [5.0]	137 [13.0]	249 [4.3]	4.5 (3.9; 5.0)	0 [0.0]	45 [3.1]	456 [23.7]	392 [30.1]	893 [15.0]	14.6 (13.6; 15.6)
	C71	6 [0.5]	7 [0.5]	8 [0.4]	2 [0.2]	23 [0.4]	0.4 (0.2; 0.6)	5 [0.4]	3 [0.2]	10 [0.5]	3 [0.2]	21 [0.4]	0.4 (0.2; 0.5)
	C72	0 [0.0]	12 [0.8]	33 [1.7]	17 [1.6]	62 [1.1]	1.1 (0.8; 1.4)	1 [0.1]	10 [0.7]	35 [1.8]	18 [1.4]	64 [1.1]	1.1 (0.8; 1.4)
	C75.1	0 [0.0]	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
	C75.2	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	C75.3	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	2 [0.1]	1 [0.1]	0 [0.0]	3 [0.1]	0.1 (0.0; 0.1)

Note: C70: Meninges; C71: Brain; C72: Spinal cord and other parts of the central nervous system; C75.1: Pituitary gland; C75.2: Craniopharyngeal duct; C75.3: Pineal gland

2.1. Tumour of the central nervous system incidence trends: by tumour behaviour

2.1.1. Tumour of the central nervous system incidence trends by behaviour in males: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Behaviour		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Malignant	**N**	453	451	428	436	452	487	478	470	456	543	508	516	539	534	539	572	497	569	721	716	772		
	CR	8.9	8.8	8.3	8.4	8.7	9.2	9.0	8.8	8.4	10.0	9.3	9.4	9.7	9.6	9.6	10.2	8.8	10.0	12.6	12.4	13.3		
	ESR2013	9.8	9.6	9.0	9.2	9.5	10.1	9.8	9.5	9.1	10.8	9.9	9.9	10.4	10.1	10.1	10.6	9.1	10.4	13.0	12.8	13.6	1.5 (0.8; 2.2)	2004-2024
																							0.5 (-1.4; 2.4)	2004-2012
																							-0.3 (-3.5; 3.0)	2013-2016
																							3.5 (1.6; 5.4)	2017-2024
Borderline	**N**	85	73	75	87	89	110	97	100	81	131	111	135	85	131	115	103	127	131	128	128	121		
	CR	1.7	1.4	1.5	1.7	1.7	2.1	1.8	1.9	1.5	2.4	2.0	2.5	1.5	2.4	2.1	1.8	2.2	2.3	2.2	2.2	2.1		
	ESR2013	1.6	1.4	1.5	1.7	1.7	2.1	1.9	1.9	1.5	2.5	2.1	2.5	1.5	2.4	2.1	1.8	2.2	2.3	2.2	2.2	2.1	1.8 (0.8; 2.8)	2004-2024
Benign	**N**							272	293	326	379	369	434	426	455	445	528	470	528	385	349	336		
	CR							5.1	5.5	6.0	7.0	6.7	7.9	7.7	8.2	7.9	9.4	8.3	9.3	6.7	6.1	5.8		
	ESR2013							5.6	5.9	6.5	7.4	7.2	8.4	8.3	8.6	8.4	9.9	8.6	9.8	7.0	6.3	6.0	0.2 (-1.0; 1.4)	2010-2024
																							7.0 (4.0; 10.0)	2010-2016

Behaviour	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
																						2.7 (-1.2; 6.7)	2017-2020
																						-11.3 (-15.3; -7.2)	2021-2024

Note: Incidence trends for benign tumours were calculated from 2010 onwards. Since 2022, the WHO classification criteria for pituitary adenomas has been updated, leading to an increase in tumours being classified and reported as malignant.

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Tumour of the central nervous system incidence trends by behaviour in females: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Behaviour		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Malignant	**N**	355	306	313	328	342	374	343	334	352	331	365	363	375	352	365	413	386	375	534	533	562		
	CR	6.7	5.7	5.8	6.1	6.3	6.8	6.2	6.0	6.3	5.9	6.4	6.4	6.5	6.1	6.3	7.1	6.6	6.4	9.1	9.0	9.4		
	ESR2013	6.9	5.9	6.0	6.1	6.4	7.0	6.3	6.1	6.4	5.9	6.5	6.4	6.6	6.1	6.2	7.0	6.6	6.3	9.0	8.9	9.3	1.7 (1.1; 2.3)	2004-2024
																							-0.3 (-1.3; 0.6)	2004-2017
																							5.6 (3.6; 7.7)	2018-2024
Borderline	**N**	65	70	76	77	93	96	95	83	104	136	113	117	110	117	134	131	118	135	150	151	133		
	CR	1.2	1.3	1.4	1.4	1.7	1.8	1.7	1.5	1.8	2.4	2.0	2.1	1.9	2.0	2.3	2.3	2.0	2.3	2.6	2.5	2.2		
	ESR2013	1.2	1.3	1.4	1.4	1.7	1.8	1.8	1.5	1.9	2.4	2.1	2.1	1.9	2.1	2.3	2.3	2.0	2.3	2.6	2.6	2.3	3.5 (2.7; 4.2)	2004-2024
																							5.9 (3.4; 8.3)	2004-2011
																							2.2 (1.0; 3.3)	2012-2024
Benign	**N**							605	629	733	763	837	860	826	914	906	958	894	1,091	952	937	982		
	CR							10.9	11.3	13.0	13.5	14.7	15.1	14.4	15.9	15.7	16.5	15.3	18.7	16.2	15.8	16.5		
	ESR2013							11.1	11.4	13.3	13.7	14.9	15.2	14.6	15.9	15.7	16.5	15.3	18.6	16.0	15.4	16.1	2.8 (1.9; 3.7)	2010-2024
																							7.5 (4.0; 11.2)	2010-2014
																							2.2 (-0.7; 5.2)	2015-2018
																							0.1 (-1.9; 2.2)	2019-2024

Note: Incidence trends for benign tumours were calculated from 2010 onwards. Since 2022, the WHO classification criteria for pituitary adenomas has been updated, leading to an increase in tumours being classified and reported as malignant.

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Tumour of the central nervous system incidence trends: by tumour location

2.2.1. Tumour of the central nervous system incidence trends by location in males: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Location		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
C70	**N**	105	111	116	144	147	175	174	176	164	199	212	241	240	259	254	271	253	266	294	296	281		
	CR	2.1	2.2	2.3	2.8	2.8	3.3	3.3	3.3	3.0	3.7	3.9	4.4	4.3	4.7	4.5	4.8	4.5	4.7	5.1	5.1	4.8		
	ESR2013	2.3	2.5	2.6	3.1	3.2	3.9	3.7	3.6	3.3	4.0	4.3	4.8	4.8	5.0	4.8	5.2	4.7	5.0	5.4	5.4	5.0	4.7 (3.9; 5.5)	2004-2024
																							11.1 (6.3; 16.1)	2004-2008
																							4.2 (0.7; 7.9)	2009-2012
																							2.8 (1.7; 3.9)	2013-2024
C71	**N**	482	480	464	478	503	546	508	519	486	592	554	572	565	572	578	596	545	620	595	587	640		
	CR	9.5	9.4	9.0	9.2	9.6	10.4	9.6	9.7	9.0	10.9	10.1	10.4	10.2	10.3	10.3	10.6	9.6	10.9	10.4	10.2	11.0		
	ESR2013	10.4	10.2	9.8	10.0	10.4	11.2	10.3	10.4	9.7	11.7	10.7	10.9	10.8	10.8	10.8	11.0	9.9	11.3	10.7	10.5	11.2	0.3 (0.0; 0.7)	2004-2024
C72	**N**	37	27	35	44	46	39	40	27	61	94	72	97	81	101	107	141	120	151	153	113	98		
	CR	0.7	0.5	0.7	0.8	0.9	0.7	0.8	0.5	1.1	1.7	1.3	1.8	1.5	1.8	1.9	2.5	2.1	2.7	2.7	2.0	1.7		
	ESR2013	0.7	0.5	0.7	0.8	0.9	0.7	0.7	0.5	1.2	1.7	1.3	1.8	1.5	1.9	1.9	2.6	2.2	2.7	2.8	2.0	1.7	6.2 (4.0; 8.4)	2004-2024
																							9.9 (7.7; 12.2)	2004-2021
																							-12.6 (-24.8; 1.6)	2022-2024
C75.1	**N**	32	53	64	76	103	71	112	133	140	150	145	154	154	177	147	184	156	172	172	178	199		
	CR	0.6	1.0	1.2	1.5	2.0	1.3	2.1	2.5	2.6	2.8	2.6	2.8	2.8	3.2	2.6	3.3	2.8	3.0	3.0	3.1	3.4		
	ESR2013	0.7	1.1	1.3	1.5	2.1	1.5	2.3	2.7	2.7	2.9	2.8	3.0	2.9	3.3	2.8	3.4	2.8	3.2	3.1	3.2	3.5	7.0 (5.7; 8.2)	2004-2024
																							17.9 (13.5; 22.4)	2004-2011
																							2.2 (-3.3; 8.1)	2012-2015
																							1.2 (-1.5; 4.0)	2016-2024
C75.2	**N**	13	10	6	6	5	8	11	5	8	13	5	17	5	9	7	3	15	12	11	11	9		

Location		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
	CR	0.3	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0.1	0.3	0.1	0.2	0.1	0.1	0.3	0.2	0.2	0.2	0.2		
	ESR2013	0.3	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0.1	0.3	0.1	0.2	0.1	0.1	0.3	0.2	0.2	0.2	0.2	0.4 (-3.0; 3.8)	2004-2024
C75.3	**N**	6	3	5	4	3	7	2	3	4	5	0	4	5	2	6	8	5	7	9	8	2		
	CR	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.2	0.1	0.0		
	ESR2013	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.2	0.1	0.0	NA	2004-2024

Note: C70: Meninges; C71: Brain; C72: Spinal cord and other parts of the central nervous system; C75.1: Pituitary gland; C75.2: Craniopharyngeal duct; C75.3: Pineal gland

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2.2. Tumour of the central nervous system incidence trends by location in females: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Location		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
C70	**N**	265	285	346	396	414	444	539	506	572	604	684	724	691	716	689	737	687	811	883	912	938		
	CR	5.0	5.3	6.4	7.3	7.6	8.1	9.8	9.1	10.2	10.7	12.1	12.7	12.1	12.4	11.9	12.7	11.8	13.9	15.0	15.4	15.7		
	ESR2013	5.1	5.5	6.6	7.5	7.8	8.3	9.9	9.2	10.4	10.8	12.1	12.9	12.2	12.5	11.9	12.6	11.7	13.7	14.8	14.9	15.3	5.3 (4.8; 5.9)	2004-2024
																							10.4 (8.1; 12.7)	2004-2010
																							5.1 (2.4; 7.8)	2011-2014
																							2.5 (1.4; 3.6)	2015-2024
C71	**N**	367	326	339	347	392	415	371	371	398	397	389	395	389	381	408	458	418	427	404	407	425		
	CR	6.9	6.1	6.3	6.4	7.2	7.6	6.7	6.6	7.1	7.0	6.9	6.9	6.8	6.6	7.1	7.9	7.2	7.3	6.9	6.9	7.1		
	ESR2013	7.1	6.2	6.5	6.4	7.3	7.7	6.8	6.7	7.2	7.1	6.9	6.9	6.8	6.6	7.0	7.8	7.1	7.2	6.8	6.8	7.0	0.2 (-0.2; 0.6)	2004-2024
C72	**N**	39	27	33	42	28	27	42	27	53	70	76	80	99	110	110	125	125	160	146	92	97		
	CR	0.7	0.5	0.6	0.8	0.5	0.5	0.8	0.5	0.9	1.2	1.3	1.4	1.7	1.9	1.9	2.2	2.1	2.7	2.5	1.5	1.6		
	ESR2013	0.7	0.5	0.6	0.8	0.5	0.5	0.8	0.5	1.0	1.3	1.4	1.4	1.8	1.9	1.9	2.1	2.2	2.7	2.5	1.6	1.6	8.5 (6.1; 10.9)	2004-2024
C75.1	**N**	51	47	75	63	91	104	82	129	147	148	153	124	124	162	176	165	152	191	184	192	194		
	CR	1.0	0.9	1.4	1.2	1.7	1.9	1.5	2.3	2.6	2.6	2.7	2.2	2.2	2.8	3.0	2.8	2.6	3.3	3.1	3.2	3.3		
	ESR2013	1.0	0.9	1.4	1.2	1.7	1.9	1.5	2.3	2.7	2.7	2.8	2.2	2.2	2.9	3.1	2.9	2.7	3.3	3.2	3.3	3.3	6.9 (5.7; 8.1)	2004-2024
																							15.1 (10.3; 20.0)	2004-2010
																							3.5 (1.9; 5.2)	2011-2024
C75.2	**N**	8	8	9	11	6	11	8	8	16	9	8	11	7	9	19	10	10	11	11	15	11		
	CR	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.1	0.3	0.2	0.1	0.2	0.1	0.2	0.3	0.2	0.2	0.2	0.2	0.3	0.2		
	ESR2013	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.3	0.2	0.1	0.2	0.1	0.2	0.3	0.2	0.2	0.2	0.2	0.2	0.2	1.1 (-0.7; 3.0)	2004-2024

Location		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
C75.3	**N**	2	3	2	7	4	3	1	5	3	2	5	6	1	5	3	7	6	1	8	3	12		
	CR	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.2		
	ESR2013	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.2	2.7 (-2.6; 8.3)	2004-2024

Note: C70: Meninges; C71: Brain; C72: Spinal cord and other parts of the central nervous system; C75.1: Pituitary gland; C75.2: Craniopharyngeal duct; C75.3: Pineal gland

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Tumour of the central nervous system incidence trends: by tumour behaviour and age group

2.3.1. Tumour of the central nervous system incidence trends in males, by behaviour and age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Malignant																								
0-19	**N**	32	28	23	23	28	36	30	33	33	34	35	34	39	36	39	23	37	36	35	28	31		
	CR	2.6	2.3	1.9	1.8	2.2	2.9	2.4	2.6	2.6	2.6	2.7	2.6	3.0	2.8	3.0	1.8	2.8	2.7	2.7	2.1	2.3		
	ESR2013	2.6	2.3	1.8	1.8	2.3	2.9	2.3	2.6	2.6	2.6	2.7	2.6	3.1	2.8	3.0	1.7	2.8	2.7	2.7	2.1	2.3	0.6 (-0.6; 1.8)	2004-2024
20-39	**N**	63	55	71	46	56	65	58	53	53	74	51	78	65	67	53	58	56	61	77	81	86		
	CR	4.4	3.9	5.1	3.3	4.0	4.6	4.1	3.7	3.7	5.2	3.6	5.4	4.5	4.6	3.7	4.0	3.8	4.2	5.3	5.5	5.8		
	ESR2013	4.4	3.9	5.1	3.3	4.0	4.6	4.1	3.8	3.7	5.2	3.6	5.5	4.6	4.7	3.7	4.0	3.8	4.2	5.3	5.6	5.8	1.0 (-0.2; 2.2)	2004-2024
40-64	**N**	186	209	169	209	194	207	212	217	191	215	232	209	217	218	222	249	204	213	306	289	332		
	CR	11.0	12.1	9.6	11.7	10.7	11.3	11.4	11.6	10.1	11.4	12.2	11.0	11.4	11.4	11.6	13.0	10.6	11.1	15.9	15.0	17.2		
	ESR2013	11.4	12.7	9.9	12.1	11.0	11.5	11.6	11.7	10.2	11.5	12.4	11.0	11.4	11.4	11.5	12.9	10.5	10.8	15.5	14.8	16.9	1.4 (0.7; 2.2)	2004-2024
																							-0.4 (-1.6; 0.8)	2004-2017
																							4.9 (2.3; 7.5)	2018-2024
65+	**N**	172	159	165	158	174	179	178	167	179	220	190	195	218	213	225	242	200	259	303	318	323		
	CR	23.4	21.3	21.9	20.9	22.9	23.2	22.7	21.0	21.8	26.2	22.2	22.2	24.3	23.3	24.1	25.4	20.5	26.2	30.1	30.9	30.6		
	ESR2013	22.2	20.1	20.7	20.2	22.1	23.0	22.4	20.7	21.7	25.9	21.9	22.0	24.3	23.3	24.2	25.3	20.4	26.2	30.0	30.8	30.4	1.9 (1.3; 2.6)	2004-2024
																							0.8 (-0.1; 1.7)	2004-2018
																							4.7 (2.3; 7.2)	2019-2024
Borderline																								
0-19	**N**	22	18	15	22	28	34	27	22	21	30	28	37	20	26	23	25	40	29	31	41	27		
	CR	1.8	1.5	1.2	1.8	2.2	2.7	2.1	1.7	1.6	2.3	2.2	2.9	1.5	2.0	1.8	1.9	3.0	2.2	2.4	3.1	2.0		
	ESR2013	1.8	1.5	1.2	1.8	2.2	2.7	2.1	1.7	1.7	2.3	2.2	2.8	1.6	2.0	1.7	1.9	3.0	2.2	2.4	3.1	2.0	2.0 (0.4; 3.7)	2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
20-39	**N**	26	13	20	14	18	25	18	18	17	25	23	24	16	18	21	9	17	29	21	16	22		
	CR	1.8	0.9	1.4	1.0	1.3	1.8	1.3	1.3	1.2	1.7	1.6	1.7	1.1	1.2	1.4	0.6	1.2	2.0	1.4	1.1	1.5		
	ESR2013	1.8	0.9	1.4	1.0	1.3	1.8	1.3	1.3	1.2	1.7	1.6	1.7	1.1	1.3	1.4	0.6	1.2	2.0	1.4	1.1	1.5	-0.2 (-2.2; 2.0)	2004-2024
40-64	**N**	29	25	23	36	30	34	26	34	23	43	28	40	30	55	46	39	47	41	43	40	37		
	CR	1.7	1.5	1.3	2.0	1.7	1.9	1.4	1.8	1.2	2.3	1.5	2.1	1.6	2.9	2.4	2.0	2.5	2.1	2.2	2.1	1.9		
	ESR2013	1.7	1.4	1.4	2.0	1.7	1.9	1.4	1.8	1.2	2.3	1.5	2.1	1.6	2.9	2.4	2.0	2.4	2.1	2.2	2.1	1.9	2.0 (0.5; 3.4)	2004-2024
65+	**N**	8	17	17	15	13	17	26	26	20	33	32	34	19	32	25	30	23	32	33	31	35		
	CR	1.1	2.3	2.3	2.0	1.7	2.2	3.3	3.3	2.4	3.9	3.7	3.9	2.1	3.5	2.7	3.1	2.4	3.2	3.3	3.0	3.3		
	ESR2013	1.2	2.1	2.3	1.9	1.6	2.1	3.1	3.2	2.4	3.9	3.6	3.6	2.1	3.5	2.7	3.1	2.4	3.2	3.3	3.0	3.3	3.6 (2.0; 5.3)	2004-2024
																							10.4 (4.8; 16.4)	2004-2011
																							0.1 (-2.4; 2.7)	2012-2024
Benign																								
0-19	**N**							10	13	11	12	11	14	12	14	13	11	19	10	11	9	8		
	CR							0.8	1.0	0.9	0.9	0.9	1.1	0.9	1.1	1.0	0.8	1.4	0.8	0.8	0.7	0.6		
	ESR2013							0.8	1.0	0.9	0.9	0.9	1.1	0.9	1.1	1.0	0.9	1.5	0.8	0.8	0.7	0.6	-1.8 (-3.9; 0.3)	2010-2024
																							3.2 (-1.0; 7.5)	2010-2018
																							-8.1 (-13.2; -2.7)	2019-2024
20-39	**N**							31	42	47	44	37	40	44	56	43	50	43	54	34	30	33		
	CR							2.2	3.0	3.3	3.1	2.6	2.8	3.1	3.9	3.0	3.4	3.0	3.7	2.3	2.0	2.2		
	ESR2013							2.2	3.0	3.3	3.2	2.7	2.8	3.1	3.9	3.0	3.5	3.0	3.8	2.3	2.1	2.3	-1.2 (-3.1; 0.8)	2010-2024
																							3.9 (0.0; 7.8)	2010-2018
																							-7.6 (-12.3; -2.7)	2019-2024
40-64	**N**							126	133	135	190	192	209	197	208	216	230	205	235	161	146	139		
	CR							6.8	7.1	7.2	10.0	10.1	11.0	10.4	10.9	11.3	12.0	10.7	12.2	8.4	7.6	7.2		
	ESR2013							6.9	7.1	7.2	10.1	10.1	11.0	10.3	10.9	11.3	12.0	10.5	12.1	8.2	7.4	7.1	0.3 (-1.1; 1.7)	2010-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
																							7.8	(5.0; 10.8)	2010-2018
																							-8.9	(-12.2; -5.5)	2019-2024
65+	**N**							105	105	133	133	129	171	173	177	173	237	203	229	179	164	156			
	CR							13.4	13.2	16.2	15.9	15.0	19.5	19.3	19.4	18.5	24.9	20.9	23.2	17.8	15.9	14.8			
	ESR2013							13.3	13.0	15.6	15.6	15.1	19.3	19.5	19.4	18.5	24.9	20.6	23.5	17.6	16.2	14.9	1.3	(0.1; 2.5)	2010-2024
																							6.7	(4.7; 8.8)	2010-2019
																							-7.8	(-11.2; -4.3)	2020-2024

Note: C70: Meninges; C71: Brain; C72: Spinal cord and other parts of the central nervous system; C75.1: Pituitary gland; C75.2: Craniopharyngeal duct; C75.3: Pineal gland

Note: Incidence trends for benign tumours were calculated from 2010 onwards. Since 2022, the WHO classification criteria for pituitary adenomas has been updated, leading to an increase in tumours being classified and reported as malignant.

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Tumour of the central nervous system incidence trends in females, by behaviour and age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Malignant																								
0-19	**N**	21	23	23	23	25	27	26	19	24	26	24	20	27	22	22	22	25	22	35	28	30		
	CR	1.8	1.9	1.9	1.9	2.1	2.2	2.1	1.6	2.0	2.1	1.9	1.6	2.2	1.8	1.8	1.8	2.0	1.8	2.8	2.2	2.4		
	ESR2013	1.8	2.0	1.9	1.9	2.1	2.2	2.1	1.5	2.0	2.1	1.9	1.6	2.2	1.8	1.8	1.8	2.0	1.8	2.8	2.2	2.4	1.2 (0.2; 2.3)	2004-2024
																							-0.3 (-1.5; 0.9)	2004-2020
																							7.6 (1.5; 14.2)	2021-2024
20-39	**N**	40	36	41	43	54	43	40	31	29	39	43	43	35	32	33	51	44	39	87	86	112		
	CR	2.9	2.6	3.0	3.1	3.9	3.1	2.9	2.2	2.1	2.8	3.0	3.0	2.4	2.2	2.3	3.5	3.0	2.7	6.0	5.9	7.6		
	ESR2013	2.9	2.6	3.0	3.1	3.9	3.1	2.9	2.2	2.1	2.8	3.1	3.0	2.5	2.3	2.3	3.6	3.1	2.7	6.0	5.9	7.6	3.8 (2.2; 5.3)	2004-2024
																							-2.2 (-4.6; 0.2)	2004-2017
																							15.8 (10.2; 21.7)	2018-2024
40-64	**N**	136	132	116	120	133	150	113	139	138	127	141	159	125	137	136	129	146	120	193	207	208		
	CR	8.0	7.7	6.6	6.7	7.4	8.2	6.1	7.4	7.4	6.7	7.5	8.4	6.6	7.2	7.2	6.8	7.7	6.3	10.1	10.8	10.8		
	ESR2013	8.3	7.9	6.9	6.8	7.5	8.3	6.2	7.5	7.4	6.7	7.5	8.4	6.6	7.2	7.1	6.7	7.6	6.1	9.9	10.6	10.7	1.1 (0.2; 2.1)	2004-2024
																							-1.2 (-2.8; 0.6)	2004-2016
																							4.7 (1.9; 7.6)	2017-2024
65+	**N**	158	115	133	142	130	154	164	145	161	139	157	141	188	161	174	211	171	194	219	212	212		
	CR	15.1	10.9	12.6	13.5	12.3	14.5	15.2	13.4	14.6	12.4	13.8	12.2	16.1	13.6	14.5	17.4	13.9	15.6	17.4	16.5	16.3		
	ESR2013	15.3	11.0	12.8	13.4	12.4	15.0	15.4	13.8	15.0	12.7	14.2	12.6	16.7	14.0	14.9	17.8	14.3	16.1	18.1	17.3	16.8	1.4 (0.7; 2.2)	2004-2024
Borderline																								
0-19	**N**	18	19	20	19	29	19	28	15	20	28	19	23	21	25	34	35	29	22	28	27	29		
	CR	1.5	1.6	1.7	1.6	2.4	1.6	2.3	1.2	1.6	2.3	1.5	1.9	1.7	2.0	2.7	2.8	2.3	1.8	2.2	2.1	2.3		
	ESR2013	1.5	1.6	1.7	1.6	2.4	1.6	2.3	1.2	1.6	2.3	1.6	1.9	1.7	2.0	2.7	2.8	2.3	1.7	2.2	2.1	2.3	1.8 (0.4; 3.3)	2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
20-39	**N**	12	14	18	18	23	24	12	16	16	32	20	17	22	19	29	24	22	35	27	25	25		
	CR	0.9	1.0	1.3	1.3	1.7	1.7	0.9	1.1	1.1	2.3	1.4	1.2	1.5	1.3	2.0	1.7	1.5	2.4	1.9	1.7	1.7		
	ESR2013	0.9	1.0	1.3	1.3	1.7	1.7	0.9	1.2	1.1	2.3	1.4	1.2	1.5	1.3	2.0	1.7	1.5	2.4	1.9	1.7	1.7	2.8 (1.1; 4.6)	2004-2024
40-64	**N**	21	26	21	20	25	28	26	33	43	47	44	47	41	48	44	49	44	44	60	53	56		
	CR	1.2	1.5	1.2	1.1	1.4	1.5	1.4	1.8	2.3	2.5	2.3	2.5	2.2	2.5	2.3	2.6	2.3	2.3	3.1	2.8	2.9		
	ESR2013	1.2	1.6	1.2	1.1	1.4	1.6	1.4	1.8	2.3	2.5	2.3	2.5	2.2	2.5	2.4	2.6	2.3	2.3	3.1	2.8	2.9	4.8 (3.7; 5.8)	2004-2024
																							7.5 (4.9; 10.2)	2004-2013
																							2.6 (0.6; 4.6)	2014-2024
65+	**N**	14	11	17	20	16	25	29	19	25	29	30	30	26	25	27	23	23	34	35	46	23		
	CR	1.3	1.0	1.6	1.9	1.5	2.3	2.7	1.7	2.3	2.6	2.6	2.6	2.2	2.1	2.3	1.9	1.9	2.7	2.8	3.6	1.8		
	ESR2013	1.3	1.0	1.7	1.8	1.5	2.3	3.0	1.9	2.4	2.6	3.0	2.7	2.3	2.3	2.3	1.9	1.9	2.9	3.0	3.7	1.8	3.6 (1.9; 5.4)	2004-2024
																							10.8 (4.9; 17.1)	2004-2011
																							-0.1 (-2.7; 2.7)	2012-2024
Benign																								
0-19	**N**							8	10	16	15	15	14	13	13	17	14	8	14	6	8	6		
	CR							0.7	0.8	1.3	1.2	1.2	1.1	1.0	1.0	1.4	1.1	0.6	1.1	0.5	0.6	0.5		
	ESR2013							0.6	0.8	1.3	1.2	1.2	1.1	1.1	1.1	1.4	1.1	0.6	1.1	0.5	0.6	0.5	-4.4 (-7.3; -1.3)	2010-2024
																							5.2 (-0.9; 11.7)	2010-2018
																							-15.9 (-22.5; -8.6)	2019-2024
20-39	**N**							80	86	84	90	85	101	90	120	127	109	114	120	65	50	60		
	CR							5.7	6.1	6.0	6.3	6.0	7.1	6.3	8.4	8.8	7.6	7.9	8.3	4.5	3.4	4.1		
	ESR2013							5.8	6.2	6.1	6.5	6.1	7.2	6.4	8.5	8.9	7.7	7.9	8.3	4.5	3.5	4.1	-3.0 (-4.9; -1.1)	2010-2024
																							5.1 (1.8; 8.4)	2010-2019
																							-16.0 (-21.0; -10.7)	2020-2024
40-64	**N**							290	315	356	415	450	459	399	448	460	510	419	562	501	463	503		

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
	CR							15.7	16.9	19.0	22.0	23.9	24.3	21.1	23.7	24.3	26.9	22.0	29.5	26.3	24.1	26.2		
	ESR2013							15.8	16.9	19.0	22.0	23.8	24.3	21.0	23.5	24.1	26.5	21.9	29.3	26.0	23.8	26.1	3.0 (1.8; 4.3)	2010-2024
																							5.6 (2.8; 8.5)	2010-2017
																							0.5 (-2.2; 3.3)	2018-2024
65+	N							227	218	277	243	287	286	324	333	302	325	353	395	380	416	413		
	CR							21.1	20.1	25.1	21.7	25.3	24.8	27.8	28.2	25.2	26.8	28.7	31.8	30.1	32.5	31.7		
	ESR2013							21.6	20.4	26.2	22.5	26.0	25.7	29.1	29.0	25.9	27.6	29.7	32.9	30.9	32.6	32.0	3.0 (2.1; 3.9)	2010-2024

Note: C70: Meninges; C71: Brain; C72: Spinal cord and other parts of the central nervous system; C75.1: Pituitary gland; C75.2: Craniopharyngeal duct; C75.3: Pineal gland

Note: Incidence trends for benign tumours were calculated from 2010 onwards. Since 2022, the WHO classification criteria for pituitary adenomas has been updated, leading to an increase in tumours being classified and reported as malignant.

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Tumour of the central nervous system prevalence: by tumour behaviour and region

3.1.1. Tumour of the central nervous system prevalence by behaviour, region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Malignant											
Belgium	**N**	617	1,608	2,164	2,540	2,830	452	1,301	1,746	2,046	2,306
	CR	10.6	27.6	37.1	43.6	48.5	7.5	21.7	29.1	34.1	38.5
	ESR2013	10.7	27.9	37.5	44.0	49.0	7.5	21.8	29.3	34.4	38.7
Brussels	**N**	48	127	185	217	247	30	97	146	180	199
	CR	7.8	20.6	30.1	35.3	40.1	4.7	15.1	22.8	28.1	31.1
	ESR2013	9.1	23.5	33.7	39.5	45.1	5.0	16.2	24.5	30.6	33.7
Flanders	**N**	382	994	1,328	1,546	1,714	294	842	1,117	1,289	1,438
	CR	11.2	29.2	39.1	45.5	50.4	8.5	24.3	32.2	37.2	41.5
	ESR2013	11.1	28.9	38.8	45.3	50.2	8.4	24.3	32.3	37.3	41.5
Wallonia	**N**	187	487	651	777	869	128	362	483	577	669
	CR	10.3	26.8	35.9	42.8	47.9	6.8	19.2	25.6	30.5	35.4
	ESR2013	10.5	27.1	36.2	43.2	48.3	6.8	19.2	25.6	30.6	35.5
Borderline											

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	117	577	1,024	1,363	1,640	127	641	1,135	1,515	1,775
	CR	2.0	9.9	17.6	23.4	28.1	2.1	10.7	18.9	25.3	29.6
	ESR2013	2.0	9.9	17.5	23.4	28.1	2.1	10.8	19.0	25.3	29.6
Brussels	**N**	12	57	96	130	157	10	59	112	152	173
	CR	2.0	9.3	15.6	21.1	25.5	1.6	9.2	17.5	23.7	27.0
	ESR2013	2.0	10.4	17.4	23.2	28.1	1.6	9.9	19.1	25.9	29.6
Flanders	**N**	78	345	615	801	965	80	377	655	868	1,018
	CR	2.3	10.1	18.1	23.6	28.4	2.3	10.9	18.9	25.1	29.4
	ESR2013	2.3	10.0	17.9	23.3	28.2	2.3	11.0	18.9	25.0	29.4
Wallonia	**N**	27	175	313	432	518	37	205	368	495	584
	CR	1.5	9.6	17.2	23.8	28.5	2.0	10.8	19.5	26.2	30.9
	ESR2013	1.5	9.6	17.2	23.7	28.4	2.0	10.9	19.5	26.1	30.9
Benign											
Belgium	**N**	315	1,846	3,641	4,742	5,342	948	4,519	8,279	10,933	12,315
	CR	5.4	31.7	62.5	81.3	91.6	15.8	75.4	138.1	182.4	205.4
	ESR2013	5.5	32.5	64.2	83.5	94.1	15.5	73.4	133.8	175.7	197.2
Brussels	**N**	15	108	214	299	344	45	280	535	758	880
	CR	2.4	17.6	34.8	48.6	55.9	7.0	43.7	83.5	118.4	137.4
	ESR2013	2.8	23.1	45.3	64.0	74.5	8.4	52.1	98.3	139.9	163.3
Flanders	**N**	204	1,185	2,316	2,998	3,378	640	2,907	5,234	6,848	7,704
	CR	6.0	34.9	68.1	88.2	99.4	18.5	83.9	151.1	197.6	222.3
	ESR2013	5.9	34.2	67.0	86.6	97.5	17.5	79.3	141.9	184.4	206.5
Wallonia	**N**	96	553	1,111	1,445	1,620	263	1,332	2,510	3,327	3,731
	CR	5.3	30.5	61.2	79.6	89.3	13.9	70.5	132.8	176.0	197.4

Region	Males					Females				
	1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
ESR2013	5.5	31.4	63.4	82.5	92.7	13.6	68.7	128.5	169.4	189.2

4.1. Tumour of the central nervous system survival: by tumour behaviour

4.1.1. Tumour of the central nervous system survival by behaviour, age group and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Behaviour	**Age group**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Males								
Malignant	All ages 19+	5,936	59.9% (58.6%; 61.2%)	42.1% (40.8%; 43.4%)	35.4% (34.1%; 36.7%)	31.8% (30.6%; 33.2%)	29.7% (28.4%; 31.1%)	23.6% (22.1%; 25.3%)
	0-19	337	84.2% (80.4%; 88.2%)	72.4% (67.8%; 77.4%)	69.1% (64.2%; 74.3%)	67.9% (62.9%; 73.2%)	67.0% (62.0%; 72.4%)	61.7% (56.2%; 67.9%)
	20-39	673	91.0% (88.8%; 93.2%)	84.4% (81.7%; 87.3%)	79.4% (76.3%; 82.6%)	74.2% (70.7%; 77.8%)	69.9% (66.1%; 73.9%)	56.7% (51.8%; 62.0%)
	40-64	2,443	68.3% (66.4%; 70.2%)	45.6% (43.6%; 47.6%)	36.9% (34.9%; 38.9%)	32.0% (30.0%; 34.1%)	29.6% (27.6%; 31.7%)	22.7% (20.3%; 25.3%)
	65+	2,483	40.0% (38.1%; 42.1%)	23.1% (21.4%; 24.9%)	17.3% (15.6%; 19.0%)	14.9% (13.3%; 16.8%)	13.1% (11.3%; 15.1%)	8.5% (6.1%; 11.9%)
Borderline	All ages 19+	1,195	96.7% (95.5%; 97.9%)	95.1% (93.6%; 96.7%)	93.7% (91.9%; 95.6%)	92.5% (90.4%; 94.7%)	91.2% (88.8%; 93.8%)	86.6% (80.6%; 93.0%)
	0-19	293	99.3% (98.4%; 100.3%)	99.0% (97.8%; 100.2%)	99.0% (97.9%; 100.2%)	99.0% (97.9%; 100.2%)	98.5% (97.0%; 100.1%)	96.4% (92.6%; 100.3%)
	20-39	192	100.0% (100.0%; 100.0%)	97.4% (95.1%; 99.8%)	96.9% (94.3%; 99.6%)	96.3% (93.4%; 99.3%)	96.4% (93.5%; 99.4%)	92.7% (85.8%; 100.1%)
	40-64	416	95.9% (94.0%; 98.0%)	94.6% (92.2%; 97.0%)	93.8% (91.2%; 96.5%)	93.2% (90.4%; 96.2%)	92.2% (89.0%; 95.5%)	86.6% (80.6%; 93.1%)
	65+	294	92.8% (89.2%; 96.6%)	90.5% (85.9%; 95.3%)	86.0% (80.3%; 92.1%)	82.1% (75.3%; 89.5%)	78.8% (70.7%; 87.9%)	72.7% (53.6%; 98.6%)
Benign	All ages 19+	4,324	96.5% (95.8%; 97.2%)	96.1% (95.2%; 97.0%)	95.8% (94.8%; 96.9%)	95.6% (94.3%; 96.9%)	95.3% (93.8%; 96.9%)	98.8% (94.8%; 102.9%)
	0-19	120	100.0% (100.0%; 100.0%)	99.2% (97.6%; 100.9%)	98.3% (95.9%; 100.8%)	98.3% (95.9%; 100.8%)	98.4% (96.0%; 100.8%)	98.5% (96.1%; 101.0%)
	20-39	421	99.6% (98.9%; 100.3%)	99.4% (98.6%; 100.3%)	99.3% (98.3%; 100.3%)	99.4% (98.4%; 100.4%)	99.5% (98.5%; 100.5%)	99.8% (98.6%; 101.0%)
	40-64	1,935	98.5% (97.9%; 99.2%)	98.5% (97.8%; 99.3%)	97.6% (96.7%; 98.6%)	97.8% (96.8%; 98.8%)	97.9% (96.8%; 99.0%)	97.8% (95.6%; 100.0%)

Behaviour	Age group	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	65+	1,848	93.4% (91.9%; 95.0%)	92.6% (90.7%; 94.6%)	92.9% (90.7%; 95.3%)	92.2% (89.5%; 95.0%)	91.5% (88.2%; 94.9%)	99.6% (90.2%; 109.9%)
Females								
Malignant	All ages 19+	4,242	60.6% (59.1%; 62.1%)	46.3% (44.8%; 47.9%)	40.4% (38.8%; 42.0%)	37.3% (35.7%; 38.9%)	34.8% (33.2%; 36.5%)	29.6% (27.6%; 31.9%)
	0-19	253	83.4% (78.9%; 88.1%)	74.0% (68.8%; 79.7%)	69.0% (63.4%; 75.1%)	67.3% (61.6%; 73.6%)	65.4% (59.4%; 71.9%)	62.9% (56.4%; 70.1%)
	20-39	558	94.6% (92.8%; 96.5%)	88.4% (85.8%; 91.2%)	84.7% (81.6%; 88.0%)	82.4% (79.0%; 85.9%)	78.0% (73.9%; 82.3%)	69.2% (62.7%; 76.3%)
	40-64	1,554	71.4% (69.2%; 73.7%)	53.7% (51.3%; 56.3%)	46.4% (43.9%; 49.1%)	42.2% (39.6%; 45.0%)	39.6% (36.9%; 42.5%)	33.6% (30.4%; 37.1%)
	65+	1,877	38.5% (36.4%; 40.9%)	24.1% (22.2%; 26.2%)	18.6% (16.8%; 20.6%)	16.1% (14.3%; 18.1%)	14.2% (12.3%; 16.3%)	10.3% (7.8%; 13.5%)
Borderline	All ages 19+	1,291	96.1% (94.9%; 97.2%)	95.3% (94.0%; 96.7%)	95.0% (93.5%; 96.5%)	94.1% (92.4%; 95.8%)	92.6% (90.6%; 94.7%)	86.0% (81.1%; 91.3%)
	0-19	271	98.9% (97.7%; 100.2%)	98.6% (97.1%; 100.0%)	98.1% (96.5%; 99.8%)	98.2% (96.5%; 99.8%)	98.2% (96.5%; 99.8%)	98.2% (96.6%; 99.9%)
	20-39	243	98.8% (97.4%; 100.2%)	98.4% (96.8%; 100.0%)	98.4% (96.8%; 100.1%)	98.0% (96.1%; 99.9%)	97.4% (95.2%; 99.7%)	95.5% (91.7%; 99.4%)
	40-64	486	96.8% (95.2%; 98.5%)	96.3% (94.5%; 98.1%)	95.5% (93.4%; 97.6%)	94.0% (91.5%; 96.5%)	92.7% (89.9%; 95.6%)	90.2% (85.9%; 94.7%)
	65+	291	89.9% (86.1%; 93.9%)	88.1% (83.7%; 92.8%)	88.4% (83.5%; 93.6%)	87.3% (81.7%; 93.3%)	83.1% (76.2%; 90.6%)	61.1% (46.4%; 80.5%)
Benign	All ages 19+	9,274	97.7% (97.3%; 98.1%)	97.4% (96.9%; 97.9%)	97.7% (97.1%; 98.3%)	97.3% (96.5%; 98.0%)	97.0% (96.1%; 97.9%)	97.2% (94.9%; 99.4%)
	0-19	113	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)	100.1% (100.1%; 100.1%)	100.1% (100.1%; 100.1%)	100.2% (100.2%; 100.2%)
	20-39	950	99.6% (99.2%; 100.0%)	99.2% (98.6%; 99.8%)	99.1% (98.4%; 99.7%)	99.1% (98.4%; 99.8%)	99.0% (98.3%; 99.8%)	98.0% (96.5%; 99.5%)
	40-64	4,700	99.1% (98.8%; 99.4%)	98.8% (98.4%; 99.2%)	98.8% (98.3%; 99.2%)	98.5% (97.9%; 99.0%)	98.0% (97.4%; 98.7%)	97.4% (96.3%; 98.6%)
	65+	3,513	95.4% (94.4%; 96.3%)	95.0% (93.9%; 96.2%)	95.8% (94.5%; 97.3%)	95.1% (93.2%; 96.9%)	95.0% (92.8%; 97.2%)	96.6% (90.7%; 102.8%)

4.2. Tumour of the central nervous system survival: by tumour behaviour and tumour location

4.2.1. Tumour of the central nervous system survival by behaviour, location, and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Behaviour	**Location**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Males								
Malignant	All	5,936	59.9% (58.6%; 61.2%)	42.1% (40.8%; 43.4%)	35.4% (34.1%; 36.7%)	31.8% (30.6%; 33.2%)	29.7% (28.4%; 31.1%)	23.6% (22.1%; 25.3%)
	C70	79	74.6% (65.1%; 85.6%)	68.5% (57.7%; 81.2%)	58.0% (46.3%; 72.5%)	54.0% (41.9%; 69.5%)	52.3% (40.0%; 68.3%)	49.3% (34.9%; 69.7%)
	C71	5,066	53.8% (52.4%; 55.2%)	33.3% (32.0%; 34.7%)	26.4% (25.2%; 27.7%)	23.0% (21.8%; 24.3%)	21.1% (19.9%; 22.4%)	15.9% (14.6%; 17.3%)
	C72	176	92.8% (88.9%; 97.0%)	88.3% (83.2%; 93.6%)	87.2% (81.9%; 93.0%)	87.4% (81.9%; 93.4%)	86.8% (80.9%; 93.1%)	86.3% (78.8%; 94.5%)
	C75.1	578	98.9% (97.5%; 100.2%)	98.7% (96.8%; 100.7%)	96.0% (92.9%; 99.1%)	94.3% (90.2%; 98.7%)	95.8% (91.5%; 100.2%)	83.2% (67.4%; 102.7%)
	C75.2	0	N<50	N<50	N<50	N<50	N<50	N<50
	C75.3	44	N<50	N<50	N<50	N<50	N<50	N<50
Borderline	All	1,195	96.7% (95.5%; 97.9%)	95.1% (93.6%; 96.7%)	93.7% (91.9%; 95.6%)	92.5% (90.4%; 94.7%)	91.2% (88.8%; 93.8%)	86.6% (80.6%; 93.0%)
	C70	338	95.1% (92.3%; 98.0%)	93.5% (90.0%; 97.2%)	91.6% (87.3%; 96.0%)	88.2% (83.1%; 93.7%)	84.4% (78.1%; 91.2%)	70.6% (54.9%; 90.7%)
	C71	562	97.3% (95.9%; 98.8%)	95.7% (93.7%; 97.7%)	93.6% (91.2%; 96.1%)	93.3% (90.7%; 96.0%)	92.5% (89.7%; 95.5%)	93.4% (89.0%; 98.0%)
	C72	183	97.8% (95.4%; 100.2%)	97.3% (94.5%; 100.2%)	98.0% (95.1%; 100.9%)	98.0% (94.8%; 101.3%)	98.9% (95.7%; 102.2%)	89.9% (80.1%; 100.8%)
	C75.1	11	N<50	N<50	N<50	N<50	N<50	N<50
	C75.2	95	95.4% (91.0%; 100.0%)	92.8% (87.2%; 98.8%)	93.8% (88.1%; 99.8%)	93.1% (86.5%; 100.1%)	94.0% (87.3%; 101.1%)	94.0% (82.1%; 107.6%)
	C75.3	7	N<50	N<50	N<50	N<50	N<50	N<50
Benign	All	4,324	96.5% (95.8%; 97.2%)	96.1% (95.2%; 97.0%)	95.8% (94.8%; 96.9%)	95.6% (94.3%; 96.9%)	95.3% (93.8%; 96.9%)	98.8% (94.8%; 102.9%)
	C70	2,221	94.6% (93.4%; 95.8%)	93.9% (92.4%; 95.4%)	93.5% (91.8%; 95.3%)	92.9% (90.8%; 95.0%)	92.5% (89.9%; 95.2%)	97.3% (90.1%; 105.0%)
	C71	212	96.9% (94.4%; 99.5%)	93.8% (90.2%; 97.6%)	92.6% (88.7%; 96.8%)	93.2% (89.2%; 97.3%)	93.0% (88.8%; 97.4%)	94.9% (90.3%; 99.7%)
	C72	797	98.9% (97.8%; 100.0%)	99.0% (97.6%; 100.5%)	99.1% (97.4%; 100.8%)	100.1% (98.2%; 102.0%)	99.9% (97.6%; 102.3%)	103.8% (98.8%; 109.1%)
	C75.1	1,103	98.6% (97.6%; 99.7%)	99.1% (97.7%; 100.5%)	98.7% (96.9%; 100.5%)	98.2% (96.1%; 100.4%)	98.1% (95.6%; 100.6%)	99.1% (93.6%; 105.1%)
	C75.2	1	N<50	N<50	N<50	N<50	N<50	N<50

Behaviour	Location	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	C75.3	4	N<50	N<50	N<50	N<50	N<50	N<50
Females								
Malignant	All	4,242	60.6% (59.1%; 62.1%)	46.3% (44.8%; 47.9%)	40.4% (38.8%; 42.0%)	37.3% (35.7%; 38.9%)	34.8% (33.2%; 36.5%)	29.6% (27.6%; 31.9%)
	C70	84	80.0% (71.6%; 89.4%)	61.5% (51.4%; 73.5%)	58.1% (47.6%; 70.9%)	51.4% (40.6%; 65.1%)	47.8% (36.7%; 62.3%)	41.5% (28.7%; 60.1%)
	C71	3,393	51.6% (49.9%; 53.4%)	34.4% (32.8%; 36.1%)	27.7% (26.1%; 29.3%)	24.8% (23.3%; 26.4%)	22.7% (21.2%; 24.3%)	18.5% (16.8%; 20.3%)
	C72	155	94.0% (90.2%; 98.0%)	94.9% (91.0%; 98.9%)	94.9% (90.7%; 99.4%)	95.1% (90.5%; 99.8%)	94.3% (89.1%; 99.8%)	93.4% (84.2%; 103.5%)
	C75.1	593	100.0% (99.3%; 100.7%)	99.7% (98.5%; 100.8%)	99.6% (98.0%; 101.2%)	97.6% (94.4%; 101.0%)	98.9% (95.6%; 102.3%)	FU<10y
	C75.2	0	N<50	N<50	N<50	N<50	N<50	N<50
	C75.3	20	N<50	N<50	N<50	N<50	N<50	N<50
Borderline	All	1,291	96.1% (94.9%; 97.2%)	95.3% (94.0%; 96.7%)	95.0% (93.5%; 96.5%)	94.1% (92.4%; 95.8%)	92.6% (90.6%; 94.7%)	86.0% (81.1%; 91.3%)
	C70	474	93.9% (91.5%; 96.3%)	93.1% (90.4%; 95.8%)	92.3% (89.3%; 95.4%)	91.1% (87.7%; 94.7%)	88.0% (83.8%; 92.4%)	73.6% (63.8%; 84.9%)
	C71	492	97.9% (96.5%; 99.3%)	97.6% (96.1%; 99.2%)	97.2% (95.5%; 99.0%)	97.1% (95.2%; 99.1%)	96.3% (94.0%; 98.7%)	94.8% (90.9%; 98.9%)
	C72	179	99.0% (97.5%; 100.6%)	99.0% (97.1%; 100.9%)	99.4% (97.5%; 101.4%)	96.1% (92.4%; 99.9%)	96.6% (92.8%; 100.4%)	97.9% (92.5%; 103.6%)
	C75.1	12	N<50	N<50	N<50	N<50	N<50	N<50
	C75.2	112	92.4% (87.5%; 97.6%)	90.8% (85.1%; 96.9%)	90.8% (84.8%; 97.2%)	91.7% (85.6%; 98.1%)	91.7% (85.2%; 98.7%)	88.9% (77.9%; 101.4%)
	C75.3	25	N<50	N<50	N<50	N<50	N<50	N<50
Benign	All	9,274	97.7% (97.3%; 98.1%)	97.4% (96.9%; 97.9%)	97.7% (97.1%; 98.3%)	97.3% (96.5%; 98.0%)	97.0% (96.1%; 97.9%)	97.2% (94.9%; 99.4%)
	C70	7,215	97.3% (96.8%; 97.8%)	97.0% (96.4%; 97.6%)	97.2% (96.5%; 97.9%)	96.5% (95.6%; 97.5%)	96.0% (94.9%; 97.2%)	96.3% (93.6%; 99.0%)
	C71	214	98.7% (97.1%; 100.3%)	98.7% (96.9%; 100.6%)	99.2% (97.3%; 101.0%)	99.0% (96.8%; 101.2%)	99.6% (97.4%; 101.8%)	95.0% (87.7%; 103.0%)
	C72	807	100.1% (99.5%; 100.6%)	99.7% (98.6%; 100.8%)	100.7% (99.5%; 101.9%)	100.8% (99.2%; 102.3%)	100.6% (98.6%; 102.7%)	107.7% (104.2%; 111.2%)
	C75.1	1,054	98.3% (97.4%; 99.3%)	98.2% (97.0%; 99.4%)	98.6% (97.3%; 99.9%)	98.9% (97.4%; 100.4%)	99.5% (97.9%; 101.1%)	96.5% (90.9%; 102.4%)
	C75.2	2	N<50	N<50	N<50	N<50	N<50	N<50
	C75.3	7	N<50	N<50	N<50	N<50	N<50	N<50

Note: C70: Meninges; C71: Brain; C72: Spinal cord and other parts of the central nervous system; C75.1: Pituitary gland; C75.2: Craniopharyngeal duct; C75.3: Pineal gland

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Tumour of the central nervous system survival trends: by tumour behaviour

5.1.1. Tumour of the central nervous system survival trends by behaviour and sex: number at risk and net survival probabilities, 2004-2024

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Behaviour	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	Malignant	2,673	51.9% (50.0%; 53.9%)	30.4% (28.7%; 32.3%)	24.4% (22.7%; 26.1%)	2,001	54.2% (52.1%; 56.5%)	33.2% (31.2%; 35.4%)	28.1% (26.1%; 30.2%)
	Borderline	509	94.5% (92.4%; 96.7%)	92.7% (90.0%; 95.4%)	90.1% (86.9%; 93.4%)	471	94.1% (91.9%; 96.4%)	91.1% (88.3%; 94.0%)	87.4% (84.0%; 90.9%)
2010-2014	Malignant	2,435	54.3% (52.3%; 56.3%)	29.8% (28.0%; 31.7%)	24.1% (22.4%; 25.9%)	1,712	52.3% (50.0%; 54.8%)	31.3% (29.1%; 33.6%)	25.8% (23.7%; 28.0%)
	Borderline	512	94.5% (92.3%; 96.7%)	90.7% (87.6%; 93.9%)	88.0% (84.2%; 91.9%)	526	94.5% (92.4%; 96.6%)	91.9% (89.3%; 94.7%)	89.1% (85.8%; 92.5%)
	Benign	1,623	97.1% (96.1%; 98.2%)	95.4% (93.7%; 97.0%)	95.3% (93.2%; 97.5%)	3,543	97.0% (96.3%; 97.7%)	96.4% (95.5%; 97.4%)	95.9% (94.6%; 97.1%)
2015-2019	Malignant	2,686	56.3% (54.5%; 58.3%)	30.7% (29.0%; 32.6%)	25.4% (23.7%; 27.2%)	1,861	54.9% (52.7%; 57.3%)	33.1% (31.0%; 35.3%)	28.3% (26.3%; 30.6%)
	Borderline	569	95.9% (94.1%; 97.8%)	92.6% (89.9%; 95.3%)	89.8% (86.4%; 93.2%)	605	96.8% (95.2%; 98.3%)	95.3% (93.2%; 97.4%)	92.3% (89.5%; 95.1%)
	Benign	2,281	96.5% (95.5%; 97.5%)	95.7% (94.3%; 97.2%)	95.3% (93.4%; 97.2%)	4,439	97.8% (97.2%; 98.3%)	97.8% (97.0%; 98.6%)	97.3% (96.1%; 98.4%)
2020-2024	Malignant	3,253	62.8% (61.1%; 64.5%)	39.5% (37.7%; 41.4%)	33.4% (31.2%; 35.8%)	2,382	65.0% (63.1%; 67.0%)	46.3% (44.2%; 48.6%)	40.1% (37.4%; 42.9%)
	Borderline	627	97.4% (95.9%; 98.9%)	94.5% (92.0%; 97.1%)	92.7% (89.0%; 96.7%)	687	95.4% (93.7%; 97.1%)	94.7% (92.6%; 96.8%)	93.6% (90.9%; 96.5%)
	Benign	2,049	96.5% (95.5%; 97.5%)	96.1% (94.5%; 97.7%)	95.2% (92.5%; 98.1%)	4,840	97.7% (97.2%; 98.3%)	97.6% (96.7%; 98.4%)	96.6% (95.2%; 97.9%)

Note: Survival trends for benign tumours were calculated from 2010 onwards. Since 2022, the WHO classification criteria for pituitary adenomas has been updated, leading to an increase in tumours being classified and reported as malignant.

5.2. Tumour of the central nervous system survival trends: by tumour behaviour and tumour location

5.2.1. Tumour of the central nervous system survival trends by behaviour, location and sex: number at risk and net survival probabilities, 2004-2024

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Behaviour	Period	Location	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Malignant	**2004-2009**	Total	2,673	51.9% (50.0%; 53.9%)	30.4% (28.7%; 32.3%)	24.4% (22.7%; 26.1%)	2,001	54.2% (52.1%; 56.5%)	33.2% (31.2%; 35.4%)	28.1% (26.1%; 30.2%)
		C70	27	N<50	N<50	N<50	67	81.9% (72.8%; 92.1%)	71.8% (60.7%; 84.9%)	62.8% (50.6%; 77.9%)
		C71	2,546	49.9% (48.0%; 51.9%)	27.6% (25.9%; 29.5%)	21.6% (20.0%; 23.3%)	1,855	51.8% (49.5%; 54.1%)	29.7% (27.7%; 31.9%)	24.6% (22.7%; 26.7%)
		C72	69	93.6% (87.5%; 100.2%)	90.9% (83.4%; 99.0%)	85.1% (75.5%; 96.1%)	54	90.9% (83.5%; 98.9%)	86.1% (77.1%; 96.1%)	81.3% (71.0%; 93.0%)
		C75.1	11	N<50	N<50	N<50	14	N<50	N<50	N<50
		C75.2	0	N<50	N<50	N<50	0	N<50	N<50	N<50
		C75.3	21	N<50	N<50	N<50	11	N<50	N<50	N<50
	2010-2014	Total	2,435	54.3% (52.3%; 56.3%)	29.8% (28.0%; 31.7%)	24.1% (22.4%; 25.9%)	1,712	52.3% (50.0%; 54.8%)	31.3% (29.1%; 33.6%)	25.8% (23.7%; 28.0%)
		C70	36	N<50	N<50	N<50	33	N<50	N<50	N<50
		C71	2,314	52.4% (50.4%; 54.5%)	26.9% (25.1%; 28.9%)	21.0% (19.4%; 22.8%)	1,612	50.0% (47.6%; 52.5%)	27.9% (25.7%; 30.2%)	22.1% (20.1%; 24.2%)
		C72	65	88.4% (80.8%; 96.7%)	85.8% (77.4%; 95.0%)	83.4% (73.6%; 94.5%)	54	94.9% (88.9%; 101.2%)	94.9% (88.9%; 101.2%)	93.7% (86.1%; 101.9%)
		C75.1	13	N<50	N<50	N<50	5	N<50	N<50	N<50
		C75.2	0	N<50	N<50	N<50	0	N<50	N<50	N<50
		C75.3	8	N<50	N<50	N<50	8	N<50	N<50	N<50
	2015-2019	Total	2,686	56.3% (54.5%; 58.3%)	30.7% (29.0%; 32.6%)	25.4% (23.7%; 27.2%)	1,861	54.9% (52.7%; 57.3%)	33.1% (31.0%; 35.3%)	28.3% (26.3%; 30.6%)
		C70	51	73.2% (61.4%; 87.2%)	50.9% (37.2%; 69.6%)	40.8% (27.5%; 60.4%)	51	76.0% (64.8%; 89.0%)	57.9% (45.1%; 74.4%)	47.9% (34.9%; 65.7%)
		C71	2,504	53.9% (51.9%; 55.9%)	27.2% (25.4%; 29.0%)	21.7% (20.0%; 23.4%)	1,694	51.7% (49.3%; 54.1%)	28.3% (26.2%; 30.5%)	23.4% (21.4%; 25.6%)
		C72	88	95.6% (91.4%; 100.0%)	91.5% (85.1%; 98.5%)	90.6% (83.6%; 98.3%)	90	93.8% (88.7%; 99.2%)	93.8% (88.7%; 99.2%)	94.1% (87.7%; 101.0%)
		C75.1	24	N<50	N<50	N<50	16	N<50	N<50	N<50

Behaviour	Period	Location	Males				Females			
			N at risk	Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		C75.2	0	N<50	N<50	N<50	0	N<50	N<50	N<50
		C75.3	20	N<50	N<50	N<50	10	N<50	N<50	N<50
	2020-2024	Total	3,253	62.8% (61.1%; 64.5%)	39.5% (37.7%; 41.4%)	33.4% (31.2%; 35.8%)	2,382	65.0% (63.1%; 67.0%)	46.3% (44.2%; 48.6%)	40.1% (37.4%; 42.9%)
		C70	29	N<50	N<50	N<50	33	N<50	N<50	N<50
		C71	2,563	53.7% (51.8%; 55.7%)	25.5% (23.7%; 27.4%)	20.1% (18.2%; 22.2%)	1,700	51.5% (49.2%; 54.0%)	26.9% (24.7%; 29.2%)	21.5% (19.2%; 24.1%)
		C72	88	89.3% (82.9%; 96.2%)	82.3% (74.0%; 91.5%)	81.6% (72.4%; 92.0%)	65	94.1% (88.4%; 100.1%)	93.4% (85.9%; 101.6%)	94.8% (87.2%; 103.1%)
		C75.1	554	98.8% (97.3%; 100.2%)	96.1% (92.9%; 99.4%)	96.0% (91.5%; 100.8%)	577	100.0% (99.3%; 100.7%)	100.0% (98.4%; 101.5%)	99.6% (96.1%; 103.3%)
		C75.2	0	N<50	N<50	N<50	0	N<50	N<50	N<50
		C75.3	24	N<50	N<50	N<50	10	N<50	N<50	N<50
Borderline	**2004-2009**	Total	509	94.5% (92.4%; 96.7%)	92.7% (90.0%; 95.4%)	90.1% (86.9%; 93.4%)	471	94.1% (91.9%; 96.4%)	91.1% (88.3%; 94.0%)	87.4% (84.0%; 90.9%)
		C70	91	93.7% (88.3%; 99.6%)	91.9% (84.3%; 100.1%)	84.2% (74.2%; 95.5%)	120	92.9% (88.3%; 97.7%)	86.9% (80.2%; 94.2%)	78.4% (70.2%; 87.7%)
		C71	282	94.2% (91.3%; 97.1%)	92.2% (88.8%; 95.6%)	90.3% (86.4%; 94.4%)	232	94.7% (91.8%; 97.7%)	92.2% (88.6%; 96.0%)	90.7% (86.5%; 95.1%)
		C72	80	97.7% (94.3%; 101.2%)	97.7% (94.3%; 101.2%)	97.2% (93.1%; 101.6%)	54	98.2% (94.7%; 101.9%)	98.2% (94.7%; 101.9%)	96.0% (90.0%; 102.4%)
		C75.1	2	N<50	N<50	N<50	3	N<50	N<50	N<50
		C75.2	47	N<50	N<50	N<50	53	87.1% (78.5%; 96.7%)	84.2% (74.5%; 95.1%)	80.5% (69.8%; 92.7%)
		C75.3	7	N<50	N<50	N<50	9	N<50	N<50	N<50
	2010-2014	Total	512	94.5% (92.3%; 96.7%)	90.7% (87.6%; 93.9%)	88.0% (84.2%; 91.9%)	526	94.5% (92.4%; 96.6%)	91.9% (89.3%; 94.7%)	89.1% (85.8%; 92.5%)
		C70	160	93.2% (88.7%; 98.0%)	87.4% (80.7%; 94.6%)	82.8% (74.6%; 91.9%)	210	92.8% (89.1%; 96.6%)	89.2% (84.3%; 94.3%)	84.4% (78.5%; 90.6%)
		C71	232	94.0% (90.9%; 97.3%)	90.8% (86.7%; 95.1%)	88.6% (83.8%; 93.7%)	191	94.0% (90.5%; 97.6%)	92.5% (88.5%; 96.8%)	90.4% (84.9%; 96.3%)
		C72	65	99.3% (96.3%; 102.3%)	96.2% (90.4%; 102.2%)	93.0% (84.8%; 102.0%)	59	98.4% (95.2%; 101.7%)	95.6% (90.2%; 101.4%)	95.1% (88.9%; 101.8%)
		C75.1	8	N<50	N<50	N<50	10	N<50	N<50	N<50
		C75.2	41	N<50	N<50	N<50	48	N<50	N<50	N<50
		C75.3	6	N<50	N<50	N<50	8	N<50	N<50	N<50

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Behaviour	Period	Location	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	2015-2019	Total	569	95.9% (94.1%; 97.8%)	92.6% (89.9%; 95.3%)	89.8% (86.4%; 93.2%)	605	96.8% (95.2%; 98.3%)	95.3% (93.2%; 97.4%)	92.3% (89.5%; 95.1%)
		C70	172	92.8% (88.5%; 97.4%)	89.3% (83.3%; 95.7%)	83.3% (75.5%; 91.8%)	227	93.9% (90.6%; 97.4%)	91.9% (87.6%; 96.5%)	87.0% (81.4%; 93.0%)
		C71	263	97.3% (95.2%; 99.5%)	92.8% (89.2%; 96.5%)	90.6% (86.5%; 94.9%)	221	99.3% (98.0%; 100.5%)	98.7% (96.7%; 100.7%)	96.6% (93.5%; 99.8%)
		C72	85	97.0% (93.1%; 101.1%)	94.9% (89.9%; 100.1%)	94.8% (89.3%; 100.6%)	90	99.0% (96.9%; 101.2%)	98.4% (95.4%; 101.5%)	95.0% (89.6%; 100.7%)
		C75.1	7	N<50	N<50	N<50	5	N<50	N<50	N<50
		C75.2	40	N<50	N<50	N<50	54	92.9% (86.3%; 100.1%)	90.4% (82.4%; 99.2%)	90.4% (82.4%; 99.2%)
		C75.3	2	N<50	N<50	N<50	10	N<50	N<50	N<50
	2020-2024	Total	627	97.4% (95.9%; 98.9%)	94.5% (92.0%; 97.1%)	92.7% (89.0%; 96.7%)	687	95.4% (93.7%; 97.1%)	94.7% (92.6%; 96.8%)	93.6% (90.9%; 96.5%)
		C70	167	97.5% (94.2%; 100.8%)	92.9% (86.8%; 99.4%)	83.3% (72.4%; 95.7%)	247	93.7% (90.5%; 97.1%)	92.6% (88.5%; 96.9%)	89.8% (83.9%; 96.2%)
		C71	299	97.2% (95.2%; 99.3%)	94.5% (91.3%; 97.9%)	95.4% (92.0%; 98.9%)	271	96.7% (94.4%; 98.9%)	96.1% (93.4%; 98.8%)	96.9% (94.2%; 99.7%)
		C72	98	98.0% (95.3%; 100.9%)	99.7% (96.9%; 102.6%)	101.8% (98.9%; 104.7%)	89	99.0% (96.7%; 101.3%)	99.5% (97.3%; 101.8%)	98.0% (93.7%; 102.6%)
		C75.1	4	N<50	N<50	N<50	7	N<50	N<50	N<50
		C75.2	55	95.0% (89.2%; 101.2%)	90.1% (81.7%; 99.4%)	91.1% (82.6%; 100.4%)	58	91.9% (84.8%; 99.5%)	90.4% (82.0%; 99.6%)	87.4% (76.2%; 100.1%)
		C75.3	5	N<50	N<50	N<50	15	N<50	N<50	N<50
Benign	**2010-2014**	Total	1,623	97.1% (96.1%; 98.2%)	95.4% (93.7%; 97.0%)	95.3% (93.2%; 97.5%)	3,543	97.0% (96.3%; 97.7%)	96.4% (95.5%; 97.4%)	95.9% (94.6%; 97.1%)
		C70	724	94.3% (92.3%; 96.4%)	92.4% (89.5%; 95.4%)	90.5% (86.7%; 94.5%)	2,650	96.5% (95.7%; 97.4%)	95.7% (94.5%; 96.8%)	95.1% (93.6%; 96.7%)
		C71	88	97.9% (94.8%; 101.0%)	98.8% (94.9%; 102.7%)	98.5% (93.3%; 103.9%)	107	96.4% (92.8%; 100.1%)	96.4% (92.8%; 100.1%)	97.1% (92.7%; 101.7%)
		C72	160	99.8% (98.0%; 101.6%)	98.4% (94.9%; 102.0%)	101.6% (97.8%; 105.5%)	154	98.9% (97.1%; 100.7%)	100.1% (98.0%; 102.4%)	101.7% (98.6%; 104.8%)
		C75.1	654	99.3% (98.1%; 100.5%)	97.2% (94.9%; 99.5%)	98.3% (95.5%; 101.1%)	639	98.4% (97.2%; 99.6%)	98.2% (96.5%; 99.9%)	96.9% (94.6%; 99.2%)
	2015-2019	Total	2,281	96.5% (95.5%; 97.5%)	95.7% (94.3%; 97.2%)	95.3% (93.4%; 97.2%)	4,439	97.8% (97.2%; 98.3%)	97.8% (97.0%; 98.6%)	97.3% (96.1%; 98.4%)
		C70	1,041	94.4% (92.7%; 96.2%)	93.2% (90.8%; 95.8%)	92.1% (88.8%; 95.5%)	3,272	97.3% (96.6%; 98.0%)	97.4% (96.4%; 98.4%)	96.5% (95.1%; 98.0%)
		C71	104	95.6% (91.5%; 99.8%)	92.3% (86.9%; 98.0%)	91.8% (86.2%; 97.9%)	109	99.1% (97.3%; 100.9%)	98.8% (96.3%; 101.4%)	98.8% (95.7%; 102.0%)
		C72	351	98.2% (96.4%; 100.0%)	97.9% (95.4%; 100.5%)	98.3% (95.0%; 101.6%)	341	100.5% (99.9%; 101.0%)	100.0% (98.0%; 102.0%)	99.5% (96.6%; 102.5%)

Behaviour	Period	Location	Males				Females			
			N at risk	Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	Net Survival Probability 1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		C75.1	785	98.6% (97.3%; 99.9%)	98.5% (96.3%; 100.6%)	98.7% (95.9%; 101.5%)	727	98.2% (97.0%; 99.3%)	98.2% (96.6%; 99.8%)	98.8% (96.8%; 100.8%)
		C75.2	1	N<50	N<50	N<50	2	N<50	N<50	N<50
		C75.3	3	N<50	N<50	N<50	2	N<50	N<50	N<50
	2020-2024	Total	2,049	96.5% (95.5%; 97.5%)	96.1% (94.5%; 97.7%)	95.2% (92.5%; 98.1%)	4,840	97.7% (97.2%; 98.3%)	97.6% (96.7%; 98.4%)	96.6% (95.2%; 97.9%)
		C70	1,180	94.6% (93.0%; 96.3%)	93.9% (91.5%; 96.4%)	92.8% (88.0%; 97.9%)	3,943	97.3% (96.7%; 98.0%)	96.9% (95.9%; 97.9%)	95.0% (93.2%; 96.8%)
		C71	108	98.1% (95.0%; 101.3%)	92.9% (87.2%; 99.0%)	94.4% (88.6%; 100.6%)	105	98.2% (95.6%; 100.8%)	99.0% (96.4%; 101.7%)	100.0% (97.3%; 102.7%)
		C72	446	99.4% (98.0%; 100.8%)	99.9% (97.6%; 102.2%)	101.8% (98.6%; 105.1%)	466	99.5% (98.6%; 100.3%)	101.0% (99.6%; 102.4%)	101.9% (99.5%; 104.3%)
		C75.1	318	97.9% (95.9%; 99.8%)	98.7% (95.6%; 102.0%)	96.3% (91.6%; 101.2%)	327	98.6% (97.0%; 100.2%)	99.2% (97.1%; 101.4%)	100.8% (98.3%; 103.5%)
		C75.3	1	N<50	N<50	N<50	5	N<50	N<50	N<50

Note: C70: Meninges; C71: Brain; C72: Spinal cord and other parts of the central nervous system; C75.1: Pituitary gland; C75.2: Craniopharyngeal duct; C75.3: Pineal gland

Note: Survival trends for benign tumours were calculated from 2010 onwards. Since 2022, the WHO classification criteria for pituitary adenomas has been updated, leading to an increase in tumours being classified and reported as malignant.

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Tumour of the central nervous system mortality: by tumour behaviour and region

6.1.1. Tumour of the central nervous system mortality by behaviour, region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Malignant																						
Belgium	2	3	2	3	1	2	4	11	14	17	28	35	61	55	63	60	31	11	8	0	411	7.4
	[0.7]	[0.9]	[0.6]	[0.9]	[0.3]	[0.5]	[1.0]	[2.9]	[3.6]	[4.6]	[7.1]	[8.7]	[16.3]	[17.3]	[23.7]	[29.5]	[24.8]	[13.8]	[25.5]	[0.0]	[7.1]	(6.7; 8.2)
Brussels	1	0	0	0	0	0	0	0	1	2	2	6	7	4	4	4	1	1	1	0	34	7.9
	[2.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[4.5]	[4.9]	[16.9]	[24.3]	[18.7]	[23.8]	[31.7]	[12.4]	[20.0]	[43.4]	[0.0]	[5.6]	(5.2; 10.7)
Flanders	1	1	2	2	1	1	1	8	8	7	18	16	34	30	39	38	24	7	5	0	243	7.2
	[0.6]	[0.5]	[1.0]	[1.0]	[0.5]	[0.5]	[0.5]	[3.8]	[3.6]	[3.3]	[7.9]	[6.6]	[14.9]	[15.3]	[23.8]	[29.2]	[29.1]	[13.0]	[24.0]	[0.0]	[7.2]	(6.3; 8.1)
Wallonia	0	2	0	1	0	1	3	3	5	8	8	13	20	21	20	18	6	3	2	0	134	7.8
	[0.0]	[1.9]	[0.0]	[0.9]	[0.0]	[0.9]	[2.5]	[2.6]	[4.3]	[6.8]	[6.4]	[10.4]	[17.1]	[20.8]	[23.4]	[29.8]	[17.4]	[14.3]	[24.3]	[0.0]	[7.4]	(6.5; 9.2)
Borderline																						
Belgium	1	0	2	0	1	0	1	3	0	2	3	6	5	7	9	13	14	12	2	0	81	1.5
	[0.3]	[0.0]	[0.6]	[0.0]	[0.3]	[0.0]	[0.3]	[0.8]	[0.0]	[0.5]	[0.8]	[1.5]	[1.3]	[2.2]	[3.4]	[6.4]	[11.2]	[15.1]	[6.4]	[0.0]	[1.4]	(1.2; 1.8)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	4	0	0	7	2.1

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[7.9]	[24.9]	[80.0]	[0.0]	[0.0]	[1.2]	(0.6; 3.7)
Flanders	1	0	1	0	1	0	0	3	0	2	1	2	4	6	6	8	9	8	2	0	54	1.6
	[0.6]	[0.0]	[0.5]	[0.0]	[0.5]	[0.0]	[0.0]	[1.4]	[0.0]	[0.9]	[0.4]	[0.8]	[1.7]	[3.1]	[3.7]	[6.1]	[10.9]	[14.9]	[9.6]	[0.0]	[1.6]	(1.2; 2.0)
Wallonia	0	0	1	0	0	0	1	0	0	0	2	4	1	1	3	4	3	0	0	0	20	1.2
	[0.0]	[0.0]	[0.9]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[0.0]	[0.0]	[1.6]	[3.2]	[0.9]	[1.0]	[3.5]	[6.6]	[8.7]	[0.0]	[0.0]	[0.0]	[1.1]	(0.7; 1.7)
Benign																						
Belgium	0	0	0	0	0	0	0	1	1	0	0	1	3	1	4	3	7	1	3	0	25	0.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.0]	[0.0]	[0.2]	[0.8]	[0.3]	[1.5]	[1.5]	[5.6]	[1.3]	[9.6]	[0.0]	[0.4]	(0.3; 0.7)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	3	0.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.7]	[5.9]	[0.0]	[0.0]	[0.0]	[43.4]	[0.0]	[0.5]	(0.0; 1.9)
Flanders	0	0	0	0	0	0	0	0	0	0	0	1	2	0	2	2	5	0	1	0	13	0.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.4]	[0.9]	[0.0]	[1.2]	[1.5]	[6.1]	[0.0]	[4.8]	[0.0]	[0.4]	(0.2; 0.6)
Wallonia	0	0	0	0	0	0	0	1	1	0	0	0	1	0	1	1	2	1	1	0	9	0.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.9]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[1.2]	[1.7]	[5.8]	[4.8]	[12.2]	[0.0]	[0.5]	(0.2; 1.0)
Females																						
Malignant																						
Belgium	5	3	0	4	2	1	2	2	6	12	15	18	32	44	41	35	25	22	6	1	276	4.4
	[1.7]	[1.0]	[0.0]	[1.2]	[0.6]	[0.3]	[0.5]	[0.5]	[1.6]	[3.3]	[3.9]	[4.5]	[8.4]	[13.0]	[13.8]	[14.2]	[14.4]	[16.4]	[8.5]	[4.8]	[4.6]	(3.9; 4.9)
Brussels	1	0	0	0	1	0	1	0	0	0	1	3	2	1	4	4	2	1	1	0	22	4.3
	[2.7]	[0.0]	[0.0]	[0.0]	[2.4]	[0.0]	[1.8]	[0.0]	[0.0]	[0.0]	[2.6]	[8.8]	[6.6]	[4.0]	[18.7]	[22.2]	[15.6]	[10.2]	[17.6]	[0.0]	[3.5]	(2.5; 6.1)
Flanders	4	2	0	3	1	0	1	2	4	8	7	11	16	28	28	19	16	15	5	1	171	4.5
	[2.5]	[1.1]	[0.0]	[1.7]	[0.5]	[0.0]	[0.5]	[0.9]	[1.8]	[3.8]	[3.1]	[4.7]	[7.0]	[13.9]	[15.9]	[12.6]	[14.6]	[17.6]	[11.4]	[8.2]	[5.0]	(3.9; 5.2)
Wallonia	0	1	0	1	0	1	0	0	2	4	7	4	14	15	9	12	7	6	0	0	83	4.2
	[0.0]	[1.0]	[0.0]	[0.9]	[0.0]	[0.9]	[0.0]	[0.0]	[1.7]	[3.4]	[5.6]	[3.2]	[11.4]	[13.5]	[9.0]	[15.5]	[13.5]	[15.5]	[0.0]	[0.0]	[4.4]	(3.3; 5.1)

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Borderline																						
Belgium	1	0	0	0	0	0	1	1	1	0	1	8	3	6	9	5	7	23	9	2	77	1.1
	[0.3]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.3]	[0.0]	[0.3]	[2.0]	[0.8]	[1.8]	[3.0]	[2.0]	[4.0]	[17.2]	[12.7]	[9.6]	[1.3]	(0.8; 1.3)
Brussels	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	1	1	0	4	0.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.9]	[0.0]	[0.0]	[4.7]	[0.0]	[0.0]	[10.2]	[17.6]	[0.0]	[0.6]	(0.0; 1.4)
Flanders	1	0	0	0	0	0	1	1	1	0	1	4	0	3	5	4	4	18	3	2	48	1.1
	[0.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[0.5]	[0.0]	[0.4]	[1.7]	[0.0]	[1.5]	[2.8]	[2.7]	[3.7]	[21.1]	[6.8]	[16.3]	[1.4]	(0.8; 1.4)
Wallonia	0	0	0	0	0	0	0	0	0	0	0	3	3	3	3	1	3	4	5	0	25	1.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[2.4]	[2.7]	[3.0]	[1.3]	[5.8]	[10.3]	[23.6]	[0.0]	[1.3]	(0.7; 1.6)
Benign																						
Belgium	0	0	0	0	0	0	0	0	0	3	1	0	0	5	2	6	7	6	9	0	39	0.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.3]	[0.0]	[0.0]	[1.5]	[0.7]	[2.4]	[4.0]	[4.5]	[12.7]	[0.0]	[0.7]	(0.4; 0.7)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[7.8]	[0.0]	[0.0]	[0.0]	[0.2]	(0.0; 0.6)
Flanders	0	0	0	0	0	0	0	0	0	2	1	0	0	3	1	6	5	2	6	0	26	0.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[0.4]	[0.0]	[0.0]	[1.5]	[0.6]	[4.0]	[4.6]	[2.3]	[13.6]	[0.0]	[0.8]	(0.4; 0.9)
Wallonia	0	0	0	0	0	0	0	0	0	1	0	0	0	2	1	0	1	4	3	0	12	0.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[0.0]	[0.0]	[1.8]	[1.0]	[0.0]	[1.9]	[10.3]	[14.2]	[0.0]	[0.6]	(0.2; 0.8)

Note: Mortality, as registered with ICD-10 C70, C71, C72.

7.1. Tumour of the central nervous system mortality trends: by tumour behaviour and region

7.1.1. Tumour of the central nervous system mortality trends in males, by behaviour and region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Malignant																							
Belgium	**N**	324	305	320	341	377	343	360	376	402	393	397	378	381	380	379	414	441	398	406	411		
	CR	6.4	6.0	6.2	6.6	7.2	6.5	6.8	7.0	7.4	7.2	7.3	6.9	6.9	6.8	6.8	7.4	7.8	7.0	7.1	7.1		
	ESR2013	7.4	7.0	7.2	7.5	8.1	7.6	7.6	7.9	8.4	8.1	8.0	7.6	7.4	7.4	7.3	8.0	8.2	7.3	7.4	7.4	0.3 (0.0; 0.7)	2004-2023
																						1.8 (0.8; 2.8)	2004-2012
																						-2.1 (-3.8; -0.4)	2013-2016
																						0.1 (-1.0; 1.2)	2017-2023
Brussels	**N**	24	22	15	35	22	31	25	28	39	25	30	24	26	30	27	26	26	25	33	34		
	CR	5.0	4.5	3.1	7.0	4.4	6.0	4.7	5.2	7.1	4.5	5.3	4.2	4.5	5.2	4.6	4.4	4.3	4.2	5.5	5.6		
	ESR2013	7.3	5.7	4.1	10.0	5.9	8.5	6.1	7.4	10.5	5.8	7.7	5.6	6.8	7.0	6.0	6.7	6.3	5.4	7.2	7.9	0.1 (-1.7; 1.9)	2004-2023
Flanders	**N**	204	193	219	200	245	213	231	239	237	240	255	241	226	216	216	268	274	253	257	243		
	CR	6.9	6.5	7.3	6.6	8.1	7.0	7.5	7.7	7.6	7.6	8.1	7.6	7.1	6.7	6.7	8.2	8.4	7.7	7.7	7.2		
	ESR2013	7.5	7.4	8.0	7.3	8.7	7.7	7.9	8.3	8.1	8.1	8.4	7.9	7.2	6.9	6.8	8.5	8.3	7.7	7.7	7.2	-0.2 (-0.7; 0.4)	2004-2023
Wallonia	**N**	96	90	86	106	110	99	104	109	126	128	112	113	129	134	136	120	141	120	116	134		
	CR	5.9	5.5	5.2	6.4	6.6	5.9	6.1	6.4	7.3	7.4	6.4	6.5	7.3	7.6	7.7	6.8	7.9	6.7	6.5	7.4		

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
	ESR2013	7.0	6.7	6.4	7.3	7.6	7.0	7.3	7.1	8.5	8.7	7.3	7.3	8.1	8.5	8.6	7.5	8.6	7.1	7.1	7.8	0.5 (-0.4; 1.3)	2004-2023
																						1.6 (0.3; 2.9)	2004-2015
																						0.2 (-3.3; 3.9)	2016-2019
																						-2.5 (-6.8; 2.1)	2020-2023
Borderline																							
Belgium	**N**	68	85	63	76	66	62	86	64	72	81	76	79	81	113	95	84	69	72	83	81		
	CR	1.3	1.7	1.2	1.5	1.3	1.2	1.6	1.2	1.3	1.5	1.4	1.4	1.5	2.0	1.7	1.5	1.2	1.3	1.5	1.4		
	ESR2013	2.0	2.2	1.6	1.9	1.6	1.6	2.0	1.5	1.6	1.8	1.7	1.7	1.7	2.4	2.0	1.7	1.3	1.4	1.6	1.5	-0.8 (-1.9; 0.3)	2004-2023
Brussels	**N**	7	5	4	0	4	3	8	4	4	3	0	4	4	4	2	4	2	0	2	7		
	CR	1.5	1.0	0.8	0.0	0.8	0.6	1.5	0.7	0.7	0.5	0.0	0.7	0.7	0.7	0.3	0.7	0.3	0.0	0.3	1.2		
	ESR2013	2.3	1.6	1.3	0.0	0.9	0.8	2.2	1.4	0.9	1.1	0.0	1.2	1.0	1.3	0.6	1.1	0.7	0.0	0.3	2.1	NA	2004-2023
Flanders	**N**	44	51	37	44	44	34	42	43	50	46	45	38	48	93	78	51	46	54	49	54		
	CR	1.5	1.7	1.2	1.5	1.4	1.1	1.4	1.4	1.6	1.5	1.4	1.2	1.5	2.9	2.4	1.6	1.4	1.6	1.5	1.6		
	ESR2013	2.1	2.2	1.6	1.8	1.9	1.5	1.6	1.6	1.8	1.8	1.7	1.4	1.6	3.1	2.6	1.7	1.4	1.7	1.6	1.6	-0.4 (-2.0; 1.3)	2004-2023
Wallonia	**N**	17	29	22	32	18	25	36	17	18	32	31	37	29	16	15	29	21	18	32	20		
	CR	1.0	1.8	1.3	1.9	1.1	1.5	2.1	1.0	1.0	1.8	1.8	2.1	1.7	0.9	0.8	1.6	1.2	1.0	1.8	1.1		
	ESR2013	1.5	2.2	1.7	2.5	1.3	1.8	2.8	1.2	1.3	2.0	2.2	2.6	2.0	1.2	1.0	1.9	1.3	1.2	2.1	1.2	-1.6 (-4.0; 0.9)	2004-2023
Benign																							
Belgium	**N**	20	19	15	19	13	24	22	26	28	25	25	19	29	16	26	20	13	26	15	25		
	CR	0.4	0.4	0.3	0.4	0.2	0.5	0.4	0.5	0.5	0.5	0.5	0.3	0.5	0.3	0.5	0.4	0.2	0.5	0.3	0.4		
	ESR2013	0.7	0.5	0.4	0.5	0.4	0.6	0.5	0.7	0.7	0.5	0.6	0.4	0.6	0.3	0.6	0.4	0.3	0.5	0.3	0.5	-2.0 (-4.0; 0.1)	2004-2023
Brussels	**N**	2	1	1	0	1	2	6	6	5	2	4	0	2	0	1	0	0	3	0	3		
	CR	0.4	0.2	0.2	0.0	0.2	0.4	1.1	1.1	0.9	0.4	0.7	0.0	0.3	0.0	0.2	0.0	0.0	0.5	0.0	0.5		
	ESR2013	0.6	0.3	0.3	0.0	0.3	0.6	1.7	2.2	1.6	0.5	1.2	0.0	0.6	0.0	0.3	0.0	0.0	0.8	0.0	0.9	NA	2004-2023
Flanders	**N**	12	11	7	10	8	13	10	11	13	14	15	9	15	10	15	12	6	16	11	13		

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
	CR	0.4	0.4	0.2	0.3	0.3	0.4	0.3	0.4	0.4	0.4	0.5	0.3	0.5	0.3	0.5	0.4	0.2	0.5	0.3	0.4		
	ESR2013	0.7	0.6	0.3	0.4	0.4	0.5	0.4	0.5	0.4	0.5	0.6	0.3	0.5	0.3	0.5	0.4	0.2	0.5	0.3	0.4	-1.7 (-4.0; 0.7)	2004-2023
Wallonia	**N**	6	7	7	9	4	9	6	9	10	9	6	10	12	6	10	8	7	7	4	9		
	CR	0.4	0.4	0.4	0.5	0.2	0.5	0.4	0.5	0.6	0.5	0.3	0.6	0.7	0.3	0.6	0.5	0.4	0.4	0.2	0.5		
	ESR2013	0.8	0.5	0.7	1.0	0.4	0.9	0.5	0.7	1.0	0.7	0.4	0.9	0.9	0.4	0.9	0.6	0.5	0.5	0.3	0.6	-1.9 (-4.7; 1.0)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Tumour of the central nervous system mortality trends in females, by behaviour and region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Malignant																							
Belgium	**N**	269	265	244	262	276	282	266	309	297	274	278	288	275	255	262	304	304	298	255	276		
	CR	5.1	5.0	4.5	4.8	5.1	5.1	4.8	5.5	5.3	4.8	4.9	5.0	4.8	4.4	4.5	5.2	5.2	5.1	4.3	4.6		
	ESR2013	5.2	5.1	4.5	4.9	5.1	5.2	4.8	5.5	5.4	4.8	4.8	5.0	4.7	4.3	4.4	5.0	5.0	4.9	4.1	4.4	-0.7 (-1.2; -0.1)	2004-2023
Brussels	**N**	20	21	25	24	21	17	22	18	23	25	20	21	21	19	16	26	26	27	28	22		
	CR	3.8	4.0	4.7	4.5	3.9	3.1	3.9	3.1	3.9	4.2	3.4	3.5	3.5	3.1	2.6	4.2	4.2	4.3	4.5	3.5		
	ESR2013	4.2	4.7	5.1	5.4	4.1	4.0	4.1	3.4	5.0	4.9	3.8	4.3	4.3	3.7	3.0	5.0	4.7	5.4	5.1	4.3	0.0 (-1.3; 1.3)	2004-2023
Flanders	**N**	158	157	121	159	163	190	159	196	175	160	168	179	161	155	157	188	178	173	155	171		
	CR	5.2	5.1	3.9	5.1	5.2	6.0	5.0	6.1	5.4	5.0	5.2	5.5	4.9	4.7	4.7	5.6	5.3	5.1	4.6	5.0		
	ESR2013	5.3	5.2	3.9	5.1	5.1	6.0	4.9	5.9	5.3	4.8	5.0	5.2	4.7	4.5	4.4	5.2	5.0	4.8	4.2	4.5	-0.6 (-1.4; 0.2)	2004-2023
Wallonia	**N**	91	87	98	79	92	75	85	95	99	89	90	88	93	81	89	90	100	98	72	83		
	CR	5.2	5.0	5.6	4.5	5.2	4.2	4.7	5.2	5.4	4.9	4.9	4.8	5.0	4.4	4.8	4.8	5.4	5.3	3.8	4.4		
	ESR2013	5.5	5.1	5.6	4.5	5.3	4.2	4.6	5.2	5.6	4.9	4.8	4.7	4.8	4.3	4.7	4.7	5.1	5.0	3.7	4.2	-0.9 (-1.7; -0.2)	2004-2023
Borderline																							
Belgium	**N**	96	88	71	87	71	83	81	88	104	80	76	63	72	118	84	83	85	65	83	77		
	CR	1.8	1.6	1.3	1.6	1.3	1.5	1.5	1.6	1.8	1.4	1.3	1.1	1.3	2.1	1.5	1.4	1.5	1.1	1.4	1.3		
	ESR2013	1.8	1.6	1.2	1.5	1.2	1.4	1.3	1.4	1.6	1.3	1.1	0.9	1.1	1.9	1.3	1.2	1.2	0.9	1.2	1.1	-1.6 (-3.0; -0.3)	2004-2023
Brussels	**N**	8	2	6	8	7	9	7	5	7	5	0	3	3	7	4	4	6	5	5	4		
	CR	1.5	0.4	1.1	1.5	1.3	1.6	1.2	0.9	1.2	0.8	0.0	0.5	0.5	1.1	0.7	0.6	1.0	0.8	0.8	0.6		
	ESR2013	1.4	0.4	1.0	1.3	1.3	1.6	1.2	0.7	1.1	0.8	0.0	0.5	0.5	1.4	0.7	0.7	1.1	0.9	0.8	0.7	NA	2004-2023
Flanders	**N**	64	56	39	45	47	43	46	54	54	44	49	42	42	86	67	53	52	38	57	48		
	CR	2.1	1.8	1.3	1.5	1.5	1.4	1.5	1.7	1.7	1.4	1.5	1.3	1.3	2.6	2.0	1.6	1.6	1.1	1.7	1.4		

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
	ESR2013	2.1	1.8	1.2	1.3	1.3	1.2	1.3	1.4	1.4	1.2	1.2	1.0	1.0	2.3	1.7	1.3	1.2	0.9	1.4	1.1	-1.4 (-3.2; 0.5)	2004-2023
Wallonia	**N**	24	30	26	34	17	31	28	29	43	31	27	18	27	25	13	26	27	22	21	25		
	CR	1.4	1.7	1.5	1.9	1.0	1.7	1.6	1.6	2.4	1.7	1.5	1.0	1.5	1.4	0.7	1.4	1.4	1.2	1.1	1.3		
	ESR2013	1.4	1.8	1.4	1.9	0.9	1.7	1.4	1.5	2.0	1.5	1.3	0.9	1.3	1.2	0.6	1.3	1.3	1.1	1.0	1.1	-2.3 (-4.2; -0.3)	2004-2023
Benign																							
Belgium	**N**	43	47	38	33	30	41	36	35	59	42	41	36	32	36	34	50	40	32	43	39		
	CR	0.8	0.9	0.7	0.6	0.6	0.7	0.7	0.6	1.0	0.7	0.7	0.6	0.6	0.6	0.6	0.9	0.7	0.5	0.7	0.7		
	ESR2013	0.8	0.8	0.7	0.6	0.5	0.7	0.6	0.6	1.0	0.7	0.7	0.6	0.5	0.5	0.5	0.7	0.6	0.5	0.6	0.6	-1.5 (-2.8; -0.1)	2004-2023
Brussels	**N**	8	5	1	5	2	8	1	4	6	7	9	3	6	5	1	9	2	5	6	1		
	CR	1.5	1.0	0.2	0.9	0.4	1.4	0.2	0.7	1.0	1.2	1.5	0.5	1.0	0.8	0.2	1.5	0.3	0.8	1.0	0.2		
	ESR2013	1.5	0.8	0.3	1.2	0.3	1.8	0.1	0.7	0.9	1.4	1.8	0.5	1.1	0.9	0.2	1.5	0.5	1.1	1.0	0.2	-1.0 (-7.3; 5.8)	2004-2023
Flanders	**N**	21	23	18	19	16	21	25	18	37	22	22	19	11	15	17	28	24	11	19	26		
	CR	0.7	0.8	0.6	0.6	0.5	0.7	0.8	0.6	1.2	0.7	0.7	0.6	0.3	0.5	0.5	0.8	0.7	0.3	0.6	0.8		
	ESR2013	0.7	0.7	0.6	0.5	0.5	0.6	0.7	0.5	1.0	0.6	0.6	0.5	0.3	0.4	0.4	0.7	0.6	0.3	0.5	0.6	-2.0 (-4.3; 0.3)	2004-2023
Wallonia	**N**	14	19	19	9	12	12	10	13	16	13	10	14	15	16	16	13	14	16	18	12		
	CR	0.8	1.1	1.1	0.5	0.7	0.7	0.6	0.7	0.9	0.7	0.5	0.8	0.8	0.9	0.9	0.7	0.8	0.9	1.0	0.6		
	ESR2013	0.8	1.0	1.1	0.5	0.6	0.6	0.5	0.7	0.9	0.6	0.5	0.8	0.7	0.7	0.7	0.6	0.6	0.7	0.8	0.5	-0.8 (-2.6; 1.1)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026